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The scope of the thesis
An adult human body is made up of different types of cells that exert a variety of 
functions but share nearly identical genomic DNA. What gives the different cells 
their morphologies, phenotypes, behaviours and functions? It is gene expression that 
determines the cell “fate”. Consequently, gene expression is an extremely important 
biological “business” in the cells that requires precise regulation. Indeed, the human 
genome is tightly and orderly packed, with genetic information in a genome held within 
genes. However, protein-coding genes only account for less than 2% of the human 
genome, so that more than 98% of regions are non-coding. Are these non-coding regions 
just garbage or very important? To answer this question, we need to explore the “dark 
matters” in our genome to better understand the functions of the non-coding regions. 
The key to understand gene regulation is comprehensive identification of the regulatory 
elements in the non-coding regions which determine where and when the protein-coding 
genes are switched on and off in the life cycle of cells. It is worth noting that over half 
of the human disease-associated genetic variants reside in non-coding regions. Adequate 
understanding of the “language of gene regulation” is particularly relevant to understand 
human diseases, especially cancer.
The focus of this thesis is on the senescence (oncogene-induced senescence)-associated 
regulatory elements in non-coding regions. Senescence serves as a suppressive barrier 
to tumorigenesis. A full understanding of the gene regulation in the process of cellular 
senescence will empower us to know more about tumorigenesis. 
In summary, the general goal of my research is to understand how the functional 
regulatory elements control gene expression. 
Cancer
Cancer is a complex collection of distinct genetic diseases with a common characteristic 
of uncontrolled cell proliferation. In general, cancer cells can be distinguished from 
normal cells through six essential alterations, also called the hallmarks of cancer (1): 
(1)  Cancer cells must self-sustain proliferative signalling to support their growth. 
(2)  Cancer cells are insensitive to anti-growth signals. 
(3)  Cancer cells develop resistance mechanisms to apoptosis, a form of intrinsic cell death. 
(4)  Cancer cells acquire unlimited proliferation potential. 
(5)  Cancer cells can attract new blood vessels, by a process called angiogenesis, to gain 
the extra oxygen and nutrients they need. 
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(6) Lastly, cancer cells may obtain the ability to invade adjacent tissues, escaping from 
the mass of the primary tumours and travel to distant locations where they colonise 
foreign locations in the body. 
Cancer cells achieve the above-mentioned phenotypes partly by modifying and re-
activating some cellular programmes that control cell proliferation, migration, apoptosis 
and differentiation. Mostly, these phenotypic traits can be explained by genetic 
alterations, such as gain-of-function mutations, overexpression or amplification of some 
key oncogenes as well as loss-of-function mutations, silencing or deletions of some key 
tumour suppressor genes (2).
Senescence: a mechanism to suppress tumorigenesis
Senescence
Cellular senescence is a state of irreversible growth arrest which can be induced by 
different stimuli, including telomere shortening, DNA damage, oxidative stress and 
oncogenic stress (Figure 1) (3). Cellular senescence was initially discovered by Hayflick 
in 1965 as the limited lifespan of primary human fibroblasts in culture (4). This was 
defined as replicative stress-induced senescence caused by telomere shortening (5, 
6). When telomeres lose protective structures and reach a critical minimal length, the 
DNA damage response and cell cycle arrest will be triggered. It is possible to artificially 
reconstitute telomerase activity by ectopic expression of telomerase reverse transcriptase 
(hTERT) in normal human cells. This leads to the elongation of telomeres, therefore 
extends the replicative lifespan allowing cellular immortalisation (6, 7). The activation of 
a telomere maintenance mechanism (TMM) is essential for cellular immortalisation, the 
hallmark of human cancers. Interestingly, many tumours possess activating mutations in 
the hTERT promoter that result in higher telomerase activity (8, 9). Alternatively, some 
tumours elongate their telomeres by a DNA recombination mechanism known as ALT 
(an alternative lengthening of telomeres)(10), thereby maintaining their telomeres at the 
length necessary for sustained proliferation. 
Oncogene-induced senescence
Another form of cellular senescence caused by excessive mitogenic signalling was 
discovered in 1997 by Serrano and colleagues (11). They found that transduction 
of the oncogenic HRASV12 gene into human embryonal fibroblasts resulted in an 
irreversible cell cycle arrest. This kind of proliferative arrest phenotypically resembled 
the replicative senescence, therefore was termed “premature senescence” or oncogene-
induced senescence (OIS). Subsequently, it was found that hyper-expression of RAS 
in mammary epithelial cells can also activate tumour suppression pathways, triggering 
irreversible growth arrest (12). OIS can also be induced by other oncogene activation, 
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such as AKT (13), BRAF (14) and E2F1 (15). Importantly, inactivation of some tumour 
suppressor genes, such as PTEN and NF1, can induce senescence (16, 17). Initially, 
DNA damage response and OIS were thought to be different cellular stress responses, 
but more recent investigations suggested that OIS was caused by the accumulation of 
DNA damage. One model showed that the oncogene-driven accumulation of reactive 
oxygen species (ROS) can induce DNA damage resulting in cell cycle arrest (18), while 
another model proposed that excessive DNA replication caused by oncogene activation 
can trigger DNA replication stress, leading to activation of the DNA damage response 
(DDR), ultimately resulting in senescence (19, 20). In line with this, OIS was reported to 
play a crucial role in protecting normal tissues from tumorigenesis (16, 21, 22).
Telomere 
attrition
DNA damage
Senescence
Oxidative 
stress
O2
O2
O2
Oncogene 
activation
RASV12
Figure 1. Senescence can be induced by different stimuli
Senescence markers
In light of the importance of senescence, identifying senescent cells in vivo can have 
important diagnostic and therapeutic potential. However, the molecular pathways 
involved in triggering and/or maintaining the senescent phenotype are still not fully 
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characterised. Consequently, the identification of senescence markers is vital. Indeed, 
increasing numbers of potential markers for senescence identification have been reported 
in recent years (Figure 2). The first and the most important marker of senescence is the 
typically flat and enlarged morphology of the senescent cells. Secondly, the detection of 
senescence-associated β-galactosidase (SA-β-Gal) activity is the most widely utilised 
assay for senescence (23). The β-Gal activity is derived from the increased lysosomal 
content of senescent cells, which enables the detection of lysosomal β-galactosidase both 
in vitro and in vivo (24). Thirdly, genomic DNA is highly packed and well-organised with 
the combination of histone proteins in chromatin, which serves as another level for gene 
regulation. Chromatin-density can be visualised by DAPI staining. Heterochromatin 
is a tightly packed form of chromatin which encompasses transcriptionally inactive 
regions in the genome, whereas euchromatin is a lightly packed form of chromatin 
with active transcription. Active and inactive chromatin regions are usually marked by 
different and specific histone modifications. It has been reported that heterochromatin 
is critical in different nuclear functions including nuclear organisation, chromosome 
segregation and gene silencing (25, 26). The DNA foci of senescent cells do not contain 
active transcription sites but, in contrast, have the heterochromatin features known 
as senescence-associated heterochromatic foci (SAHF) (27). SAHFs constitute the 
typically morphological nuclear feature of senescent cells widely exploited to identify 
senescence. Fourth, the senescent cells do not proliferate, exhibiting expression of genes 
related to repressed cell cycle. There are two main signalling pathways involved in the 
initiation and establishment of senescence, RB (retinoblastoma)-p16INK4a and p53-p21.
High levels of p16INK4a and p21 expression can be detected in senescent cells (28–30), and 
it is well established that these two pathways have a central role in tumour suppression. 
• Large flattened morphology
• Senescence-associated β-galactosidase activity (SA-β-Gal)
• Senescence-associated heterochromatic foci (SAHF)
• senescence-associated secretory phenotype (SASP): IL6, IL8
• Irreversible proliferation arrest, changes in gene expression
cell cycle gene             p16INK4a or p21 
Non-Senescent cells Senescent cells
Figure 2. Features of senescent cells
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Importantly, mutations in these two pathways are frequently found in tumours (31–33). 
Fifth, senescent cells secrete cytokines, such as IL6 and IL8, which reinforce the senescence 
(34). In fact, none of the above-mentioned markers solely represent senescence, so it 
is good practice to use a combination of different markers to identify senescent cells. 
Gene regulatory elements 
Genetic alterations of the human genome, such as mutations, deletions, and amplifications 
are the main causes of diseases. Interestingly, the human genome consists of only around 
2% of protein-coding genes, with the majority of our genome (98%) being non-coding, 
which was previously considered as “junk DNA”. However, the so-called non-coding 
junk regions contain functional elements, such as microRNAs, long-non-coding RNAs 
(lncRNA), promoters, enhancers, insulators, silencer, and chromatin structure moieties. 
The human body is made up of numerous cell types having a wide variety of specialised 
roles with the nearly identical genome. In its essence, this diversity of functions can 
be explained by regulating the transcriptional output of different genes in specific cell 
types, conditions, and developmental stages through numerous regulatory elements. 
Obviously, gene expression is a crucial biological process that requires precise and 
careful regulation. Uncovering the interplay between gene coding regions and regulatory 
regions is therefore essential to understand the mechanisms governing gene regulation 
in health and disease (35). Interestingly, it seems that mutations in functional regulatory 
regions are one of the major causes of gene expression deregulation in diseases. However, 
we have a very incomplete understanding of how many regulatory elements exist in the 
human genome and what their functions are in gene regulation. Therefore, it is very 
important, though quite challenging, to identify and functionally characterise regulatory 
elements in the human genome.
Identification of regulatory elements
The first step in understanding the biological function of regulatory elements is their 
identification. The development of high-throughput DNA sequencing methods enabled 
the identification of gene regulatory elements on a genome-wide scale. Some of the 
most popular techniques for this purpose include (A) DNase sequencing (DNase-seq) 
and the assay for transposase-accessible chromatin using sequencing (ATAC-seq), (B) 
chromosome conformation capture assays, and (C) chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) (Figure 3). 
The DNase-seq(36) and ATAC-seq(37) allow us to identify the regulatory elements by 
taking advantage of open and accessible nucleosome regions. Unfortunately, they cannot 
determine the functional roles of the identified elements.
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The DNase-seq (36) and ATAC-seq (37) allow the identification of regulatory elements 
by taking advantage of open and accessible nucleosome regions. Unfortunately, they 
cannot determine the functional roles of the identified elements.
ChIP-seq can detect the specific regulatory elements depending on the antibody (against 
transcription factors (TFs), cofactors, or histone markers) used. ChIP-seq was commonly 
used to detect specific TF binding regions through the genome. Usually, TF binding 
regions are promoters or enhancers. For histone markers, three methyl groups on the 
lysine in position 4 of histone H3 (H3K4me3) are used as a marker to detect active 
promoters (38), whereas a single methyl group on the lysine in position 4 of histone H3 
(H3K4me1) is a marker for enhancers (39). An acetyl group on the lysine in position 
27 of histone H3 (H3K27ac) is another marker used to detect active enhancers (40, 41). 
More histone marks such as trimethylation of histone H3 on lysine 27 (H3K27me3) and 
di- or trimethylation of histone H3 on lysine 9 (H3K9me2/3) are commonly utilised to 
identify silenced regions(42). 
Chromatin conformation capture assays identify the interactions between genomic loci, 
such as promoter-enhancer interactions, by fixing the interactions followed by ligation 
and sequencing or PCR. The advantage of this technique is that it detects not only the 
regulatory elements but also can identify target genes.
A large research consortia used the methodologies detailed above to explore the functions 
of the non-coding genome, leading to increased annotation of the regulatory genome 
landscape. For example, the Encyclopedia of DNA Elements (ENCODE) project 
(43, 44) identified and mapped histone modification marks, TF binding sites, DNase 
I hypersensitive sites, chromosome interaction maps, DNA methylation patterns, and 
the binding sites of RNA-binding proteins. The Functional Annotation of Mammalian 
Genome (FANTOM) project has mapped the TFs, sets of transcripts, enhancers, and 
promoters in several major primary mammalian cells by using the cap analysis of gene 
expression (CAGE) (45, 46). The Epigenome Roadmap project has mapped histone 
modifications, DNA methylation, small RNA transcripts and chromatin accessibility in 
stem cells (47, 48). All these projects provided a comprehensive insight into the regulatory 
elements landscape in the human genome. However, functional annotation of regulatory 
DNA elements lags behind. Consequently, large-scale and robust functional assays are 
required to elucidate the role of regulatory elements during normal development and in 
disease.
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Figure 3. Genome-wide methods to identify gene regulatory elements. 
(A) Gene regulatory elements are usually located in active regions of the genome where there 
are open chromatin regions and can be digested by enzymes, such as DNase I or modified Tn5 
transposons, followed by massively parallel sequencing to identify them (DNase-seq or ATAC-seq). 
(B) Gene regulatory elements can be identified using the antibody against a specific TF, followed by 
immunoprecipitation and deep sequencing to identify the regions bound by specific TF (ChIP-seq). 
(C) Gene regulatory elements can be identified by proximity ligation methods (e.g., 3C, 4C, 5C, and 
Hi-C), which require cross-linking distal interacting DNA (such as enhancer and promoter) followed 
by sequencing to map the interactions. Abbreviations: ATAC-seq, assay for transposase-accessible 
chromatin using sequencing; 3C, chromosome conformation capture; 4C, circularised chromosome 
conformation capture; 5C, carbon copy chromosome conformation capture; ChIP-seq, chromatin 
immunoprecipitation followed by massively parallel sequencing; DNase-seq, DNase sequencing; TF, 
transcription factor.
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LncRNAs: RNA regulatory element
RNA was considered as a messenger operating between DNA and protein. However, only 
2% of the human genome contains protein-coding genes which can be transcribed into 
messenger RNA (mRNA). Over the last decades, the development of high-throughput 
technologies, such as next-generation sequencing, have allowed the in depth exploration 
of the non-coding genome. Notably, it has been increasingly and well demonstrated 
that the genome of many species, including human, is pervasively transcribed, resulting 
in the production of a huge amount of non-coding transcripts which were previously 
considered as “transcription noise”. Especially, some large-scale RNA profiling studies 
have shown that the majority of the human genome (>75%) is actively transcribed, 
forming a highly complicated network of non-coding transcripts (ncRNAs) and protein-
coding transcripts (or mRNAs) (49, 50).
Long-non-coding RNAs (LncRNAs) are defined as RNAs that are larger than 200 bp 
without protein-coding potential (51). There is increasing evidence indicating that 
lncRNAs are involved in numerous biological processes including cell differentiation 
and development (52), antiviral response (53), and gene imprinting (54). It has been 
reported that deregulation (overexpression, deficiency or mutation) of lncRNAs is related 
to different diseases including cancers (55, 56, 57). While the majority of the lncRNAs 
are not characterised and their functions are unknown, some lncRNAs were well 
investigated. Generally, the mechanisms of lncRNAs function can be broadly divided into 
cis-regulating expression and/or chromatin state of nearby locus/gene or trans-functions 
throughout the cells (58–60). The key point to distinguish cis and trans regulation is 
whether the lncRNAs activities are found where they come from and neighbouring loci 
(cis) or somewhere else (trans). A well-characterised example of cis-function lncRNA 
is the X inactive specific transcript (XIST) in X chromosome inactivation (61). More 
studies have effectively demonstrated the sequence-specific requirements of XIST during 
the X inactivation (62, 63). In some cases, lncRNAs production is important for local 
gene regulation and this regulation is independent of its sequence. A classic example of 
this kind of regulation is the antisense lncRNA-Airn (antisense Igfr2 RNA non-coding), 
which overlaps with the Igfr2 gene body and promoter; moreover, it is important to 
silence the paternal allele. It has been demonstrated that Airn silencing regulation 
depends on the antisense transcription and importantly, is independent of the Airn 
sequence (64). In addition, it should also be considered that the lncRNA cis-regulatory 
activity is due to the DNA elements within the locus that functions independently of 
the sequences or production of the lncRNAs. LincRNA-P21 was initially reported to 
function as a P53-dependent trans-acting lncRNA by repressing a gene network in the 
P53 signalling pathway during DNA damage and apoptosis (65). Later investigation of 
the lincRNA-P21 locus revealed that actually, lincRNA-P21 regulates CDKN1A (P21) 
in cis (66), which was further confirmed by its short half-life and low copy number (66). 
These findings indicated the role of lincRNA-P21 as cis-acting lncRNA, which is in line 
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with another report that lincRNA-P21 acts as an enhancer RNA to regulate CDKN1A 
(67). In addition to these cis-regulatory lncRNAs, there is an increasing number of reports 
of lncRNAs that can leave the site of transcription and operate in trans. Such lncRNAs 
can be categorised into at least three major subgroups. First, lncRNAs can regulate gene 
expression and/or chromatin states far away from the transcription site, such as HOTAIR 
(68). Second, lncRNAs can regulate the nuclear architecture, the most-well investigated 
example being MALAT1(69, 70). Third, lncRNAs can influence the interacted proteins 
and/or other RNAs, for instance, lncRNA NORAD acts as the decoy for RNA-binding 
proteins PUMILIO1 and PUMILIO2 (71, 72).
In summary, the discovery of lncRNAs as crucial RNA regulatory elements has revealed 
a new layer of genome regulation.
Enhancers: DNA regulatory element
Gene transcription is an important process during cellular development and the generation 
of different cell types within an organism. Thus, gene expression needs precise, accurate 
and robust regulation, strictly controlled by the interplay of various regulatory events. 
The promoter is a critical DNA regulatory element that can initiate the transcription of a 
gene. Besides promoters, enhancers have also been identified as key regulators of gene 
transcription. In 1981, the first enhancer was identified and characterised as a 72 bp DNA 
sequence of the SV40 virus (73, 74). Soon thereafter, many enhancers were discovered, 
and their functional properties have been extensively studied. Enhancers are defined as 
DNA sequences that activate gene transcription in cis, but independent of their relative 
location, distance, and orientation to their target promoters. 
Genes are often controlled by multiple enhancers, each of which can provide diverse 
transcriptional regulation and modulate the level of gene expression under different 
biological circumstances. Thus, enhancers are extremely critical players in the response 
to the changes and demands of different environmental, developmental, and physiological 
conditions. It is worth noting that deregulation of enhancers is closely related to human 
diseases including cancers (75–79).
Enhancers are usually 100–1000 bp long and contain short DNA motifs that function 
as binding sites for TFs. TFs can recruit co-activators or co-repressors and determine 
the activity of the enhancer based on the combined regulatory cues of all bound factors. 
Generally, activation of enhancers requires multiple TFs binding, usually including 
lineage-specific factors and sequence-dependent factors which maintain the integration 
of intrinsic and extrinsic cues at enhancers (80). Mutations or alterations in the TFs 
binding motifs can abolish enhancer activities, leading to the deregulation of their target 
gene expression (81). The consensus TFs binding motifs on enhancers are often used 
for identification of putative enhancers (82). In addition, active enhancers are typically 
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devoid of nucleosomes. These regions are “open” and sensitive to DNA nucleases like 
DNase I, thus their chromatin is more accessible to be bound by TFs (82, 83). This 
“open”-chromatin accessibility is also used for the prediction of enhancers. Furthermore, 
a genome-wide effort to map histone modification on chromatin has revealed specific 
patterns with different marks that are enriched at promoters, active enhancers, and 
transcriptionally silent or repressed regions. These marks allow the prediction of 
enhancers on a genome-wide scale (39, 41, 84–86). It has been shown that active 
enhancers are typically marked by a high level of histone H3 lysine 4 monomethylation 
(H3K4me1) and H3K27 acetylation (H3K27ac) (41, 87). The combination of the 
above described “enhancer features” is frequently used for genome-wide prediction 
of enhancers. Recently, it has been shown that active enhancers produce RNAs, so-
called enhancer-associated RNAs (or eRNAs) (45). The expression of eRNAs is highly 
correlated with enhancer activities and their target gene expression (88, 89), therefore 
can be utilised as a marker of active enhancers for systematic annotation of enhancers 
across the genome (45). Nevertheless, our knowledge about enhancers is rudimentary. 
Functional identification and characterisation of enhancers is currently an area of great 
interest and a major genomic challenge. 
CRISPR-Cas system 
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 
(Cas) system was found as RNA mediated adaptive defence system in bacteria and 
archaea that protects them from invading viruses and plasmids (90, 91). This defence 
system can detect and silence “foreign” nucleic acids in a sequence-specific manner, 
relying only on small RNAs. In response to the viral infection and plasmid challenges, 
the short fragments of foreign DNA from virus or plasmid (known as the protospacer) 
are integrated into the host chromosome in a repeat-spacer-repeat manner at the CRISPR 
array (92, 93). The “CRISPR repeat-spacer” loci are then transcribed and processed into 
short CRISPR-derived RNAs (crRNAs), which contain the sequence complementary to 
protospacer sequences from the invading nucleic acid (94–96). After that, the crRNAs 
direct the detection and silencing of the target foreign DNA with Cas proteins by packing 
them together into a surveillance complex (93, 97–99). 
Type-II CRISPR from S. pyogenes was the first engineered system for genome editing 
(100), opening the gate for the manipulation of the human genome in a very effective 
and efficient manner. The most widely used version of this system is CRISPR-Cas9 
which requires Cas9 nuclease and single guide RNA (sgRNA). The sgRNA is a fusion 
of crRNA and trans-activating CRISPR RNA (tracrRNA), which pairs with crRNA and 
guides the CRISPR-associated protein Cas9 to cleave the target DNA. The site-specific 
cleavage requires a short protospacer adjacent motif (PAM) in the target DNA (NGG 
in S. pyogenes). This Cas9 system is currently widely and successfully used to edit and 
target endogenous genes in human cells and even organisms (101–104). 
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Traditionally, the manipulation of non-coding regions in the genome was mainly 
dependent on homologous recombination techniques (105–107). Genome engineering 
technologies, such as synthetic zinc finger (ZF) proteins and transcription activator-
like effectors (TALEs), facilitated the development of genome research, however, they 
were unsuitable for large-scale high-throughput functional analyses of regulatory DNA 
elements (for review see 108). The development of the CRISPR-Cas9 system overcame 
this, allowing functional screens to annotate regulatory DNA elements using functional 
genetic screening approaches (109).
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ABSTRACT
Oncogene-induced senescence (OIS), provoked in response to oncogenic activation, 
is considered an important tumour suppressor mechanism. Long-noncoding RNAs 
(lncRNAs) are transcripts longer than 200 nucleotides without a protein-coding capacity. 
Functional studies showed that deregulated lncRNA expression promote tumorigenesis 
and metastasis and that lncRNAs may exhibit tumor-suppressive and oncogenic. Here, 
we first identified lncRNAs that were differentially expressed between senescent and 
non-senescent human fibroblast cells. Using RNA interference, we performed a loss-
function screen targeting the differentially expressed lncRNAs, and identified lncRNA-
OIS1 (lncRNA#32, AC008063.3 or ENSG00000233397) as a lncRNA required for 
OIS. Knockdown of lncRNA-OIS1 triggered bypass of senescence, higher proliferation 
rate, lower abundance of the cell cycle inhibitor CDKN1A, and high expression of cell 
cycle associated genes. Subcellular inspection of LncRNA-OIS1 indicated nuclear and 
cytosolic localization in both normal culture conditions as well as following oncogene 
induction. Interestingly, silencing lncRNA-OIS1 diminished the senescent-associated 
induction of a nearby gene (Dipeptidyl Peptidase 4, DPP4) with established role in tumor 
suppression. Intriguingly, similar to lncRNA-OIS1, silencing DPP4 caused senescence 
bypass, and ectopic expression of DPP4 in lncRNA-OIS1 knockdown cells restored 
the senescent phenotype. Thus, our data indicate that lncRNA-OIS1 links oncogenic 
induction and senescence with the activation of the tumor suppressor DPP4.
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INTRODUCTION
Next-generation sequencing and microarray technologies uncovered thousands of long 
non-coding RNAs (lncRNAs) encoded in the human genome(1, 2). The majority of those 
lncRNAs are transcribed and processed in a similar manner to mRNAs, however, lack 
protein-coding potential(3, 4). Although it is still unclear how many of those lncRNAs 
have a significant biological function, some of them have been found to be crucial 
players in the regulation of cellular processes such as proliferation, differentiation 
or development, as well as in a progression of a variety of human diseases including 
cancer(5–10). It has been shown that lncRNAs are key determinants of epigenetic 
regulation, modulation of chromatin structure, scaffolding or decoy function of mRNAs, 
and post-transcriptional mRNA regulation(11–15).Gene regulation by lncRNAs can be 
a result of cis-action on nearby genes, or in trans by modulating mRNA stability, mRNA 
translation, or microRNA and RNA-binding-protein function(16–23).
Cellular senescence was initially defined by Hayflick in 1965 as the limited lifespan of 
primary human fibroblasts in culture(24). It is a state of irreversible growth arrest which 
can be induced by different stimuli such as telomere shortening, DNA damage, oxidative 
stress or oncogene activation(25). Serrano et al., were the first to observe that primary 
human and mouse fibroblasts enter senescence following the induction of oncogenic 
RAS, a process termed oncogene induced senescence (OIS)(26). Cellular senescence 
has been studied most extensively as a strong tumor suppressive mechanism against 
the emergence of oncogenes(27). Moreover, there is evidence indicating for a role of 
senescence in age-related conditions and diseases, including cancer, cardiovascular 
diseases, neurodegeneration, diabetes, sarcopenia, and declining immune function in 
the elderly(28–32). In contrast, senescent cells can also contribute to tumorigenesis by 
secreting interleukins (e.g., IL-6, IL-8, and IL-1a), metalloproteases (e.g., MMP-1, and 
MMP-3) and other cytokines (e.g., granulocyte-macrophage colony-stimulating factor 
(GM-CSF)), as part of the senescence associated secretory phenotype(SASP)(25, 30, 
33–37). Therefore, senescence may either suppress or promote tumour progression 
depending on the context where it occurs(38, 39). Given the impact of senescence on 
human physiology and pathology, it is of interest to understand the molecular mechanisms 
underlying senescence in order to utilize it for diagnosis and therapy.
A number of factors have been implicated in regulating senescence, including 
transcription factors, RNA binding proteins, and microRNAs, such as p53, Ets(40), 
HuR(41), AUF1(42) and TTP(43), and miR-377(44), miR-22(45). In contrast, despite 
increasing interest in the expression and function of lncRNAs, their possible implication 
in senescence remains largely unexplored. Recent works indicated a role of MIR31HG 
and SALNR in senescence(46)(47), but a focused functional genetic screen was not 
described before. We therefore sought to identify senescence-associated lncRNAs 
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using our established cellular system that induces senescence in  primary human BJ 
fibroblasts(48). Using transcriptomic profiling we identified a number of differentially-
expressed lncRNAs following oncogene induction. Next, using functional screen, we 
discovered that one of lncRNAs whose expression was induced upon oncogenic stress 
-lncRNA-OIS1- is required for OIS. We demonstrate that lncRNA-OIS1 is required
for senescence by controlling a nearby DPP4 gene with a tumor suppressive activity.
Collectively, our results provide a new lncRNA-mediated regulatory pathway for
controlling DPP4 during OIS. Our findings support the role of lncRNAs as transcriptional
regulators in critical processes such as cellular senescence and a potential role in cancer.
Material and methods
cell culture, transfection, retroviral and lentiviral transduction
BJ/ET/RasV12, TIG3/ET/RASV12, Ecopack 2 and HEK293-T cells were cultured in 
DMEM medium (Gibco), supplemented with 10% FCS (fetal calf serum) (Hyclone), 
and 1% penicillin/streptomycin (Gibco). Senescence was induced by treatment with 
100 nM 4-OHT (Sigma) for 14days. Retroviruses were made by calcium phosphate 
transfection of Ecopack 2 cells and harvest at 40 and 64 h later. Lentiviruses were made 
by PEI (polyethylenimine) transfection of HEK293T. Medium was refreshed after 16h 
and collect the lentivirus by filtering through a 0.45 µm membrane (Milipore Steriflip 
HV/PVDF) 40 h post-transfection and stored at −80 °C. Cells were selected with the 
proper selection medium 48 h after transduction for at least 4 days until no surviving 
cells remained in the no-transduction control plate.
RNA-seq and analysis
RNA-seq samples were processed with TruSeq RNA library prep kit v2 (Illumina) and 
sequenced in a HiSeq 2500 (Illumina). Sequenced reads were aligned to the human genome 
(hg19) using TopHat2(49) and gene expression levels were counted using HTseq(50) and 
normalized using quantile normalization. To avoid inflation of lowly-expressed genes 
among the genes called as differentially expressed, we applied a dynamic cut-off which 
takes into account that technical variation varies with expression level. Specifically, in 
the comparison between two conditions, we divided the genes into 20 bins according to 
their average expression level, and calculated the standard deviation (SD) of fold-change 
within each bin. Genes whose expression was changed by at least 1.75-fold and this 
fold-change was above the bin’s 1.75 SD (dashed curve in Fig 1B and 3B) were called 
as differentially expressed. To further avoid false positive calls among lowly expressed 
genes we set a floor level of 5 counts (that is, any level below 5 was set to 5). Functional 
enrichment analysis was done using DAVID(51). Global characterization of pathways 
that were de-regulated upon knockdown of lncRNA-OIS1 was done using Gene Set 
Enrichment Analysis (GSEA)(52).
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In situ hybridization
In situ hybridization was performed using double-FAM labeled LNA (locked 
nucleic acid) probes (Exiqon) as described previously(53). Briefly, cells were fixed, 
permeabilized and pre-hybridized in hybridization buffer and then hybridized at 55°C 
for 1 h with LNA probes for lncRNA-OIS1: 5-TTGAAAACCCATCACTCCT-3, or with 
a scramble probe 5-TGTAACACGTCTATACGCCCA-3 as negative control, all at 25 
nM. Cells were subsequently incubated with 3% hydrogen peroxide to block potential 
endogenous peroxidase, and then probes were detected with peroxidase-conjugated 
anti-fluorescein-Ab (Roche applied Sciences) diluted 1:400 followed by addition of 
Cy3-labeled TSA substrate for 10 minutes (Perkin Elmer). All cells were mounted 
with ProLong®GoldAntifade Mountant containing DAPI nuclear stain (ThermoFisher 
Scientific). Images were acquired using a Zeiss Axio Imager Z1 epi-fluorescence 
microscope equipped with an AxioCamMRm CCD camera and a Plan-APOCHROMAT 
63x/1.4 objective (Zeiss). Within the same experiment, images were acquired at the same 
exposure conditions.
BrdU proliferation assay
BJ and TIG3 Cells were pulsed for 3 h with 30 µM bromodeoxyuridine (BrdU, Sigma), 
washed two times with PBS and then fixed with 4% formaldehyde, wash two times with 
PBS and treated with 5M HCl/0.5% Triton to denature DNA and neutralized with 0.1M 
Na2B4O7, incubated with anti-BrdU (Dako) for 2 hours in RT after half hour blocking 
with 3% BSA in 0.5% Tween PBS, washed in blocking buffer (PBS, Tween 0.5%, 3% 
BSA) three times, and finally incubated with FITC-conjugated anti-mouse Alexa FLOUR 
488 secondary antibody (Dako) for 1 hour, washed three times, stained with propidium 
iodide for half hour. BrdU incorporation was measured by immunofluorescence (at least 
300 cells were scored for each condition).
Senescence-associated β-galactosidase assay
BJ and TIG3 cells were transduced with different shRNAs constructs, plated in triplicate 
and treated with 100 nM 4-OHT for 14 days. β-galactosidase activity was determined by 
using the kit (Cell Signaling), and at least 300 cells were analyzed for each condition.
Ribosome profiling (Ribo-seq)
BJ Cells were treated with cycloheximide (100 μg/ml) for 5 minutes, and lysed 20 
mM Tris-HCl, pH 7.8, 100 mM KCl, 10 mM MgCl2, 1% Triton X-100, 2 mM DTT 
(dithiothreitol), 100 μg/ml cycloheximide, 1X complete protease inhibitor. Lysates were 
centrifuged at 1,300g and the supernatant was treated with 2 U/μl of RNase I (Invitrogen) 
for 45 min at room temperature. Lysates were fractionated on a linear sucrose gradient 
(7% to 47%) using the SW-41Ti rotor at 36,000 rpm for 2h. Fractions enriched in 
monosomes were pooled and treated with proteinase K (Roche, Mannheim, Germany) 
in a 1% SDS solution. Released RNA fragments were purified using Trizol reagent 
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and precipitated in the presence of glycogen. For libraries preparation, RNA was gel-
purified on a denaturing 10% polyacrylamide urea (7 M) gel. A section corresponding 
to 30 to 33 nucleotides, the region where most of the ribosome-protected fragments 
are comprised, was excised, eluted and ethanol precipitated. The resulting fragments 
were 3′-dephosphorylated using T4 polynucleotide kinase (New England Biolabs Inc. 
Beverly, MA, USA) for 6 h at 37°C in 2-(N-morpholino) ethanesulfonic acid (MES) 
buffer (100 mM MES-NaOH, pH 5.5, 10 mM MgCl2, 10 mM β-mercaptoethanol, 300 
mM NaCl). 3′ adaptor was added with T4 RNA ligase 1 (New England Biolabs Inc. 
Beverly, MA, USA) for 2.5 h at 37°C. Ligation products were 5′-phosphorylated with 
T4 polynucleotide kinase for 30 min at 37°C. 5′ adaptor was added with T4 RNA ligase 
1 for 18 h at 22°C. The library was sequenced in illumina HiSeq2000 machine. The data 
was analysed as described(54).  
GRO-seq
Briefly, 5 × 106 nuclei were isolated and incubated 5 min at 30 °C with equal volume of 
reaction buffer (10 mM Tris-Cl pH 8.0, 5 mM MgCl2, 1 mM DTT, 300 mM KCL, 20 
units of SUPERase In, 1% sarkosyl, 500 µM adenosine triphosphate (ATP), (Guanosine 
triphosphate) GTP and Br-Uridine triphosphate (UTP), 0.2 µM CTP+32P Cytidine 
triphosphate (CTP) for the nuclear run-on. The reaction was stopped and total RNA 
was extracted with Trizol LS (Invitrogen) according to the manufacturer’s instructions. 
RNA was fragmented using fragmentation reagents (Ambion) and the reaction was 
purified through p-30 RNase free spin column (BioRad). BrU-labeled RNA was 
immunoprecipitated with anti-BrdU agarose beads (Santa Cruz), washed one time in 
binding buffer, one time in low salt buffer (0.2× SSPE, 1 mM EDTA, 0.05% Tween-20), 
one time high-salt buffer (0.25× SSPE, 1 mM EDTA, 0.05% Tween-20, 137.5 mM NaCl) 
and two times in TET buffer (TE with 0.05% Tween-20). RNA was eluted with elution 
buffer (20 mM DTT, 300 mM NaCl, 5 mM Tris-Cl pH 7.5, 1 mM EDTA and 0.1% 
SDS) and isolated with Trizol LS. After the binding step, BrU-labeled RNA was treated 
with tobacco acid pyrophosphatase (TAP, Epicenter) to remove 5′-methyl guanosine 
cap, followed by T4 polynucleotide kinase (PNK; NEB) to remove 3′-phosphate group. 
BrU-containing RNA was treated with T4 PNK again at high pH in the presence of 
ATP to add 5′-phosphate group. The reaction was stopped and RNA was extracted with 
Trizol LS. Sequencing libraries were prepared using TruSeq Small RNA kit (Illumina) 
following manufacturer’s instructions. Briefly, end-repaired RNA was ligated to RNA 3′ 
and 5′ adapters, followed by RT-PCR amplification. cDNA was purified using Agencourt 
AMPure XP (Beckman Coulter) and amplified by PCR for 12 cycles. Finally, amplicons 
were cleaned and size-selected using Agencourt AMPure XP (Beckman Coulter), 
quantified in a Bioanalyzer 2100 (Agilent), and sequenced in a HiSeq 2500 (Illumina). 
Sequenced reads were aligned to the human genome (hg19) using bowtie2(55).
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RNA isolation, reverse-transcription and quantitative real-time PCR 
(qPCR)
Total RNA was extracted by using TRIsure (Bioline) reagent and following the 
manufacturer’s protocol. cDNA was produced with SuperScript III (Invitrogen) using 4 
µg of total RNA per reaction. qPCR reaction was performed with SYBR green I Master 
mix in a LightCycler 480 (Roche). Primers used in qPCR are listed in Supplementary 
Table S5.
Western blot analysis
Whole-cell lysates were prepared as previously described(56). Membranes were 
immunoblotted with the following antibodies: CDKN1A (Sc-397, Santa Cruz; 1: 1,000), 
HRAS (C-20, Santa Cruz; 1: 1,000), DPP4 (ab28340, abcam; 1: 2,000), GAPDH 
(Sc-47724, Santa Cruz; 1: 5,000). Protein bands were visualized using corresponding 
secondary antibodies (Dako) and ECL reagent (GE Healthcare).
Chromosome conformation capture combined with sequencing (4C-seq)
Briefly, BJ cells were treated with or without 4-OHT for 14 days and 107 of cells for each 
condition were harvested and we performed 4C as previously described(57). An adapted 
two-step 4C-PCR was performed as previously described(58) to introduce template 
specific indexes. We had two viewpoints and used the following primers in the first PCR:
vp1_forward
A AT G AT A C G G C G A C C A C C G A G AT C T A C A C T C T T T C C C T A -
C A C G A C G C T C T T C C G A T C T C T T T G C T A C T C T G T G A G A T C 
vp1_reverse
ACTGGAGTTCAGACGTGTGCTCTTCCGATCTATAGGGCTCTGGAGTCAG 
vp2_forward
A AT G AT A C G G C G A C C A C C G A G AT C T A C A C T C T T T C C C T A -
C A C G A C G C T C T T C C G A T C T G T A T T T C T C T A G C T G G G A T C 
vp2_reverse
ACTGGAGTTCAGACGTGTGCTCTTCCGATCAACCGTAAAGTCTTCGCTC
We used the forward primers from the first PCR and combined the following reverse 
primers for the second PCR:
BJ – 4-OHT rep1
CAAGCAGAAGACGGCATACGAGAT  CGTGAT  GTGACTGGAGTTCAGACGT-
GTGCT
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BJ– 4-OHT rep2
CAAGCAGAAGACGGCATACGAGAT  GCCTAA  GTGACTGGAGTTCAGACGT-
GTGCT
BJ + 4-OHT rep1
CAAGCAGAAGACGGCATACGAGAT  GGAACT  GTGACTGGAGTTCAGACGT-
GTGCT
BJ + 4-OHT rep2
CAAGCAGAAGACGGCATACGAGAT  GCGGAC  GTGACTGGAGTTCAGACGT-
GTGCT
LncRNA-OIS1 expression analysis in tumors
Gene expression data was obtained from the TCGA Data Portal (https://tcga-data.nci.
nih.gov). We selected those cancer types with transcriptome data available for at least 
five normal and five tumor samples, belonging to phenotypes “solid tissue normal” and 
“primary solid tumor”, respectively. Lowly expressed genes (genes with raw read counts 
in less than half the normal samples and half the tumor samples) were removed within each 
cancer type data. Differential expression analysis was carried out with R/Bioconductor 
package limma(59) using voom normalization(60). Pearson correlation calculation was 
carried out using normalized gene expression values, also in R/Bioconductor.
RESULTS
Genome-wide identification of lncRNAs responsive to OIS
To identify lncRNAs with a role in OIS, we used the model of primary human BJ 
fibroblasts expressing hTERT and 4-OH-tamoxifen (4-OHT)-inducible oncogenic 
H-RasV12 (BJ/ET/RasV12ER cells) (48). RNA sequencing (RNA-seq) in senescent cells 
and non-senescent control cells revealed senescence-associated differentially expressed 
transcripts (Fig. 1B). Of those transcripts, we found 34 and 6 lncRNAs upregulated and 
downregulated respectively during OIS (Supplementary Table S1). Ribosome profiling 
confirmed the non-coding nature of these RNAs (Fig. 1C). We also confirmed by qRT-
PCR the induction of some lncRNAs following H-RasV12 induction (Supplementary Fig. 
S1A).
A focused loss-of-function screen for lncRNAs required for OIS identifies 
lncRNA-OIS1.
To examine possible causal roles for lncRNAs in OIS, we developed RNAi tools to 
target the 40 lncRNAs that were differentially expressed in OIS. We generated a pooled 
library consisting of 5 different shRNAs against each lncRNA, and included 4 non-
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targeting shRNAs as negative controls, as well as two positive control shRNAs targeting 
BRD7– a gene identified as a tumour suppressor in OIS(48)(Supplementary Table S2). 
We transduced cells with three independent retroviral pools of the shRNAs library, and 
following puro selection harvested half of each cell population as control (T0, Time 0). 
We cultured the rest of the cells with 4–OHT treatment for 4 weeks, then harvested the 
cells (T4, Time 4weeks) and performed next-generation sequencing to identify shRNAs 
enriched in the final populations (T4) compared to the initial (T0) pool (Fig. 1D).
Our screen detected the positive control shRNAs against BRD7, as well as few shRNAs 
targeting different lncRNAs enriched in the RAS-induced cell populations, suggesting 
that the knockdown of these lncRNAs conferred a growth advantage in BJ/ ET cells 
expressing RasV12 (Fig. 1E). For further validation, we selected two hits: lncRNA#32, 
which has one shRNA (shRNA3) at the top of the enrichment list in all three replicates, and 
another shRNA (shRNA2) giving minor enrichment; and lncRNA#30 with two shRNAs 
(shRNA5 and shRNA3) showing consistent enrichment in all three replicates (Fig. 1E 
and Supplementary Table S3). We validated the hits by repeating the OIS experiment 
using individual shRNAs. We used an shRNA targeting BRD7 (BRD7_shRNA4) as 
a positive control, and two non-targeting shRNA as negative controls. A proliferation 
assay (using BrdU labelling) indicated bypass of oncogene-induced cellular arrest by 
one shRNA (#30-5) targeting lncRNA#30 and two shRNAs (#32-2 and #32-3) targeting 
lncRNA#32 (Fig. 2A and Supplementary Fig. S2A). To further examine the effect of 
loss-of lncRNA#30 and #32 in OIS, we measured the induction of senescence-associated 
β-galactosidase (SA-β-Gal). In comparison with negative control cells, a marked 
decrease in SA-β-Gal was observed in RasV12-expressing BRD7-knockdown (BRD7 kd), 
lncRNA#30-5 and lncRNA#32-2 and #32-3 cells (Fig. 2B and supplementary Fig. S2B). 
In contrast, shRNA (#30-3) was not validated as expected from the screen outcome. 
Interestingly, RNA expression analysis indicated that only shRNAs #30-5, #32-2 and 
#32-3 were effective towards their lncRNA targets, suggesting on-target activity (Fig. 
2C, 2D). To exclude off-target effects of the shRNAs, we designed additional vectors 
targeting lncRNA#30 and #32 (Supplementary Table S6), and repeated the proliferation 
and SA-β-Gal assays. This experiment identified more functional shRNAs (#32-8, 
#32-9) targeting lncRNA#32, but no additional shRNAs targeting lncRNA#30 (Fig. 
2E, 2F and supplementary Fig. S3A, S3B). qRT-PCR confirmed loss-of expression of 
lncRNA#32 by all four active shRNA vectors (#32-2, 3, 8 and 9) (Fig. 2H). In contrast, 
two new shRNAs (#30-8, #30-9) showed efficient loss-of lncRNA#30 (Fig. 2G) but did 
not induce bypass of OIS (Fig. 2E, 2F and supplementary Fig. S3A, S3B), indicating that 
the bypass of OIS by shRNA#30-5 was not mediated by its targeted lncRNA. Altogether, 
these results demonstrate that lncRNA#32 is both induced by oncogenic RAS and is 
required for the establishment of the OIS phenotype. 
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To further solidify the role of lncRNA#32 in OIS we made use of a dual CRISPR-Cas9 
system(61), and induced deletions of the lncRNA#32 locus. As BJ cells do not form 
single clones, generation of monoclonal population of deleted cells was not possible. 
Instead, we performed a functional genetic experiment to test whether the cells containing 
the lncRNA#32 deletion are enriched in cells undergoing OIS. Notably, supplementary 
Fig. S4A shows that control-transduced BJ cells completely senesced, p53 knockout BJ 
cells strongly bypassed OIS, and targeting lncRNA#32 attenuated senescence, albeit to 
a lesser extent than p53KO. To confirm that the dual CRISPR-Cas9 system triggered 
deletion of lncRNA#32, we isolated genomic DNA and performed semi-quantitative 
PCR to detect lncRNA#32 with oligos (FW: TGGAGGGCTGAATCATCAAGTT, REV: 
ACTTCAAAGGGCAATTGCTGAAC) surrounding the CRISPR-target region. While 
wild type and control-transduced cells produced only one band of about 1.8Kb, cells 
transduced with the lncRNA#32-targeting vector showed lncRNA#32 deleted bands 
(~ 350bp), indicating the functionality of the CRISPR vector (Supplementary Fig. 
S4B). Intriguingly, the PCR signal of the deletion band increased after 2 and 3 weeks 
following OIS induction, in line with a bypass of the OIS phenotype. In comparison, 
no enrichment of the deleted allele was noted following 3 weeks of culturing without 
induction of OIS (Supplementary Fig. S4B). This indicates that lncRNA#32 deletion 
gives growth advantage only under OIS conditions. As expected, we found by qRT-PCR 
that cells expressing sgRNAs targeting lncRNA#32 have reduced level of lncRNA#32 
(Supplementary Fig. S4C). Sanger sequencing confirmed the correct deletion of 
lncRNA#32 (Supplementary Fig. S4D). For simplicity and in conjunction with its 
function, we hereafter refer to lncRNA#32 as lncRNA-OIS1. 
To extend our finding on the role of lncRNA-OIS1 in OIS we employed a different 
cell system. We transduced all four functional shRNAs targeting lncRNA-OIS1 (#32-
2, 3, 8 and 9, which we renamed KD1, 2, 3, and 4, respectively) into TIG3 cells 
expressing hTERT and 4-OH-tamoxifen (4-OHT)-inducible oncogenic H-RasV12, and 
repeated the BrdU labelling and SA-β-Gal experiments. First, q-RT-PCR and GRO-seq 
analysis indicated up-regulation of lncRNA-OIS1 following oncogenic RAS induction 
(Supplementary Fig. S5E, S9A). Second, as expected, the introduction of all four 
lncRNA-OIS1 shRNAs reduced lncRNA-OIS1 expression (Supplementary Fig. S5E). 
Last, and most profoundly, all four lncRNA-OIS1 shRNAs very effectively bypassed OIS 
as measured by the proliferation and senescent assays BrdU and SA-β-Gal, respectively 
(Supplementary Fig. S5A, S5B, S5C, S5D). Altogether, our results demonstrate that 
intact lncRNA-OIS1 is required for senescence induction following RASV12 activation 
in primary human cells.
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Figure 1. shRNAs screen identifies a lncRNA required for OIS. 
(A) A screening strategy of detecting functional lncRNAs. (B) RNA-seq comprehensively identified 
differentially expressed transcripts (mRNAs and long non-coding RNAs) in senescent cells (treated with 
4-OHT for 14 days) compared to untreated cells. (C) Ribosome profiling confirmed that the identified 
OIS lncRNAs have no protein coding capacity. Shown are selected examples and GAPDH as control. 
(D) The functional genetic screen procedure. NGS, next-generation sequencing. (E) Enrichment score 
calculated for each shRNA vector based on its prevalence in the pool, harvested after 4 weeks of 
tamoxifen (4-OHT) treatment (RASv12 induction), relative to its prevalence in the T0 pool. The plot 
shows the distribution of standardized enrichment scores (Z-scores) for the entire shRNA library.
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Figure 2. Functional validation of selected lncRNAs. 
(A) The proliferation of the various shRNA-transduced BJ-RASv12 cells was quantified using BrdU 
assay, **P < 0.0005, two-tailed Student’s t-test. For every condition, the percentage of BrdU-positive 
cells was normalized to negative control cells. (B) Senescent cells were quantified using SA-β-gal 
assay, **P < 0.0005, two-tailed Student’s t-test. For every condition, the percentage of β-gal-positive 
cells was normalized to negative control cells. (C, D) qRT–PCR analysis of lncRNA#30 and #32 in the 
various shRNA-transduced cells treated with 4-OHT relative to untreated cells. Data were normalized 
to a housekeeping gene and the levels in untreated cells set to 1, **P < 0.0005, two-tailed Student’s 
t-test. (E, F) Validation of additional shRNA-transduced BJ-RASv12 cells was performed as in panel A 
and B. BrdU (**P < 0.001) and SA-β-gal assay (**P < 0.0005) were quantified by two-tailed Student’s 
t-test. (G, H) qRT–PCR analysis of lncRNA #30 and #32 in the shRNA-transduced cells presented in 
E and F. Data were normalized to a housekeeping gene and the levels in untreated cells set to 1, **P < 
0.0005, two-tailed Student’s t-test.
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Knockdown of lncRNA-OIS1 abolishes OIS gene expression signature
Next, we sought to explore the mode of action of lncRNA-OIS1 in senescence. To this 
goal, we first performed RNA-seq of cells transduced with shRNAs against lncRNA-
OIS1, the positive controls p53 and BRD7, and negative controls (Fig. 3A). Comparison 
of gene expression profiles in negative controls and p53kd cells upon activation of 
oncogenic RAS (the former enters senescence while the latter bypasses it) identified 885 
differentially-expressed genes (386 up- and 499 down-regulated in senescent cells) (Fig. 
3B). Functional enrichment analysis showed that the set of genes whose expression was 
significantly repressed in senescent cells (compared to the p53kd cells) was markedly 
enriched for cell-cycle related genes (Fig. 3C), reflecting the strong proliferation arrest that 
is imposed in negative control cells upon oncogenic stress. This sharp down-regulation 
of cell-cycle genes defines a molecular signature that characterizes the induction of the 
senescent physiological state. Remarkably, knocking–down lncRNA-OIS1 significantly 
abolished the repression of these genes (Fig. 3D). The effect observed for lncRNA-
OIS1-kd was comparable to the effect obtained by BRD7-kd but weaker than the effect 
elicited by p53-kd (Fig. 3D). In accordance with the phenotypic effect of OIS-bypass, 
we observed that lncRNA-OIS1-kd resulted in attenuation of the induction of CDKN1A 
(p21), a prime target of p53 that is required for OIS in BJ cells (55)(Supplementary. 
S6A). We confirmed this result at the protein level using western blot analysis (Fig. 
3E and supplementary Fig. S6B). We included one shRNA (#32-6) which did not give 
knockdown of lncRNA-OIS1 and showed no bypass of the senescence phenotype (Fig. 
3E and supplementary Fig. S6B) to demonstrate specificity of the decreased expression 
of CDKN1A due to lncRNA-OIS1-kd. 
To further characterize the effect of knocking-down lncRNA-OIS1 on the cellular 
transcriptome, we systematically compared, using GSEA analysis(52)，gene expression 
profiles in cells induced for oncogenic RAS, and transduced either with shRNAs against 
lncRNA-OIS1 or with non-targeting shRNAs. As expected from the phenotypic effect 
and inline with the above analysis, the strongest gene sets that were up-regulated upon 
knocking-down lncRNA-OIS1 were related to proliferation and cell-cycle (Supplementary 
Fig. S6C). A set of genes that are induced in response to ionizing irradiation (IR) was 
the most significantly down-regulated gene set in the lncRNA-OIS1 kd cells. This set 
contains numerous p53 direct target genes, indicating that attenuated expression of 
lncRNA-OIS1 compromises the activation of the p53 network (Supplementary Fig. 
S6C). In addition, genes of the oxidative phosphorylation pathway are down-regulated 
too in the lncRNA-OIS1 kd cells. Notably, all these gene sets show the opposite response 
in cells that enter senescence in response to oncogenic stress (Supplementary Fig. S6C), 
demonstrating that loss of lncRNA-OIS1 abolishes OIS gene expression signature. 
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Figure 3. LncRNA-OIS1 knockdown shows a gene expression signature characteristic of 
senescence bypass. 
(A) A scheme of the RNA-seq experiment. RNA was collected from positive and negative control 
cells, and the various lncRNA-OIS1kd cells treated with 4-OHT for 14 days. Cells knocked-down for 
p53 and BRD7 served as positive controls. (B) The comparison of gene expression profiles between 
p53kd and negative control cells, both treated with 4-OHT to induce oncogenic RAS, identified 885 
differentially expressed genes. 386 and 499 genes were up- and down-regulated, respectively. (C) 
Enriched functional categories in the set of genes that were downregulated in the senescent cells. As 
expected, the enriched categories are related to cell proliferation and cell division. (D) For each of the 
conditions that we examined, we calculated the distribution of fold-change of expression for the set of 
135 cell-cycle genes whose expression is down-regulated in senescence, relative to their expression in 
control untreated cells. In control cells, 4-OHT treatment resulted in strong suppression of this set of 
genes (Ctr1, Ctr2 samples). In contrast, in lncRNA-OIS1-kd cells, the expression of these cell-cycle 
genes was elevated compared to control cells. Notably, the effect observed in lncRNA-OIS1kds was 
similar to the effect of BRD7, but, as expected, weaker than that of the p53kd. (E) CDKN1A protein 
levels examined by western blotting.
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Loss-of lncRNA-OIS1compromises the induction of DPP4 by OIS
To investigate the mechanism(s) by which lncRNA-OIS1 affects OIS induction, we 
first examined its subcellular localization. In control BJ/ET/RasV12ER cells, lncRNA-
OIS1 was located both in the nucleus and the cytosol. Following RASV12 activation, 
lncRNA-OIS1 maintained a similar pattern in these two compartments (Fig. 4A). In situ 
hybridization (ISH) analysis confirmed lncRNA-OIS1 increased expression following 
RASV12 induction, and its localization in the nucleus and cytosol. Loss-of lncRNA-OIS1 
confirmed the specificity of the signal to lncRNA-OIS1 (Fig. 4B). 
LncRNAs can impact the expression of nearby genes on the chromatin (Cis function), or 
affect gene expression in trans (for example by controlling mRNA transcription, splicing, 
and translation). We therefore firstly interrogated whether lncRNA-OIS1 functions in 
trans, and whether ectopic expression of lncRNA-OIS1 can drive cells into senescence 
without RAS induction. We over-expressed lncRNA-OIS1 in primary BJ cells (full 
length or exons; Supplementary Fig. S7A), but observed no induction of senescence as 
measured by BrdU labelling and SA-β-Gal assays (Supplementary Fig. S7B, S7C, S7D). 
Secondly, we overexpressed lncRNA-OIS1 (both full length and exons) in lncRNA-OIS1-
kd cells to test whether ectopic expression of lncRNA-OIS1 can restore the senescence 
phenotype. However, despite the high expression of lncRNA-OIS1 (Supplementary 
Fig. S8A), OIS-bypass by lncRNA-OIS1-kd was maintained (Supplementary Fig. S8B, 
S8C, S8D). These data indicated that lncRNA-OIS1 does not function in trans, rather, a 
localized expression and effect on neighbouring genes is required (cis effect).
In general, lncRNAs can be physically linked to the locus from which they are encoded, 
and exert its function during transcription without the need for processing or shuttling. 
Well-studied examples of cis-acting lncRNAs are those that cause X-inactivation(62)
(63). Examples of other cis-regulatory lncRNAs include ncRNA-a1-7, Hottip, and 
Mistral, the perturbation of which lead to decreased expression of nearby genes(64)(65)
(66)(67), suggesting that gene regulation in cis is a very important mode of lncRNA 
action. To investigate whether lncRNA-OIS1 expression influences nearby genes, we 
analysed Global Run-On Sequencing data (GRO-Seq) of senescent and proliferation BJ 
cells(55). We observed that both lncRNA-OIS1 and its nearby gene DPP4 were increased 
in the BJ cells upon RAS induction (Fig. 4C). We also observed the same effect in TIG3 
cells (Supplementary Fig. S9A). Additionally, loss-of lncRNA-OIS1 abolished the 
activation of DPP4 following oncogene induction based on BJ cells RNA-seq data 
(Supplementary Fig. S9B). We solidified these results by qRT-PCR (Fig. 4D and 
supplementary Fig. S9C) and chose the best two lncRNA-OIS1 knockdowns (KD2 and 
4) for western blot analyses of DPP4 expression four days following RASV12 induction, 
before the cell cycle is arrested and senescence is established (Fig. 4D, E). Indeed, 
attenuated activation of DPP4 protein expression was obtained in cells with lncRNA-
OIS knockdown. A similar effect was also observed in TIG3 lncRNA-OIS1-kd cells 4 
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Figure 4. LncRNA-OIS1 expression is required for the activation of DPP4 in response to 
oncogenic stress. 
(A) Subcellular localization of lncRNA-OIS1 in BJ cells treated with or without 4-OHT. U2 and S14 
RNAs were used as controls for nucleus and cytosol fractions, respectively. (B) In situ hybridization 
of lncRNA-OIS1 in BJ cells treated with or without 4-OHT. (C) Screenshots of GRO-seq data of 
the lncRNA-OIS1 and DPP4 genomic locus. R1 and R2 are two biological replicates. (D) qRT–PCR 
analysis of DPP4 expression upon lncRNA-OIS1kd treated with or without 4-OHT, **P < 0.002, two-
tailed Student’s t-test. (E) DPP4 protein levels examined by western blotting.
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days following RASV12 induction (Supplementary Fig. S9D). Altogether, these data link 
lncRNA-OIS1 to regulation of DPP4 expression and to the senescent phenotype induced 
by oncogenic RAS.
Loss-of DPP4 bypasses OIS
Interestingly, it has been reported that DPP4 is a tumor suppressor in melanoma (68)(69), 
non-small cell lung cancer (70), ovarian cancer(71)(72)(73), endometrial carcinoma(74), 
prostate cancer(75), neuroblastoma(76), and glioma(77). We therefore hypothesized 
that the tumour suppressive role of DPP4 is linked to OIS. To examine this issue, we 
generated shRNAs (Supplementary Table S7) transduced DPP4 knockdown BJ cells. 
qRT-PCR and western blot analyses confirmed significant reduction of DPP4 mRNA and 
protein levels upon knockdown (Fig. 5A, B). 
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Figure 5. Induction of DPP4 is required for OIS. 
(A) qRT–PCR analysis of DPP4 expression upon DPP4 kd (two different shRNAs) treated with or 
without 4-OHT, **P < 0.005, two-tailed Student’s t-test. (B) Western blot analysis of DPP4 protein. (C) 
BrdU proliferation analysis of DPP4 kd BJ-RASv12 cells, **P < 0.0005, two-tailed Student’s t-test. The 
percentage of BrdU-positive cells was normalized to negative control cells. (D) Senescence SA-β-gal 
assay. **P < 0.0005, two-tailed Student’s t-test. The percentage of β-gal-positive cells was normalized 
to negative control cells.
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As predicted, loss-of DPP4 bypassed OIS, as determined by proliferation and SA-β-Gal 
assays (Fig. 5C, D and supplementary Fig. S9E). Next, we examined whether lncRNA-
OIS1 regulates senescence through DPP4. We cloned DPP4 in a lentiviral vector, 
ectopically-expressed it in lncRNA-OIS1-kd cells, and induced OIS. Intriguingly, 
proliferation (BrdU labelling) and SA-β-Gal assays demonstrated that ectopic expression 
of DPP4 abolished the senescence bypass phenotype of lncRNA-OIS1-kd cells, while 
a control vector did not (Figure. 6A, 6B and supplementary Fig. S10A, S10B). We 
confirmed the overexpression of DPP4 by western blot (Figure. 6C and supplementary 
Fig. S10C). These experiments indicate that DPP4 is the relevant target gene of lncRNA-
OIS1 during OIS, and that lncRNA-OIS1 is a major determinant of DPP4 function in OIS.
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Figure 6. Ectopic expression of DPP4 induces senescence in lncRNA-OIS1 kd cells. 
(A) BrdU proliferation assay of DPP4 or vector-transduced BJ-RASv12-lncRNA-OIS1kd cells. **P < 
0.001, two-tailed Student’s t-test. The percentage of BrdU-positive cells was normalized to negative 
control cells. (B) SA-β-gal assay. **P < 0.001, two-tailed Student’s t-test. The percentage of β-gal-
positive cells was normalized to negative control cells. (C) Western blot analysis of DPP4 protein. 
(D) TCGA data analysis of lncRNA-OIS1 and DPP4 expression in prostate adenocarcinoma (PRAD) 
samples (r = 0.469, pvalue = 2.5e-31).
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Figure 7. Schematic representation of lncRNA-OIS1 function in normal and senescence 
conditions. 
Association of LncRNA-OIS1and DPP4 in the tumors
Last, we interrogated lncRNA-OIS1 expression in tumors and its correlation with that of 
DPP4 by analysing TCGA data. LncRNA-OIS1 is very lowly expressed in most tumor 
types (Supplementary Fig. S11A). We plotted the read counts of the lncRNA-OIS1 among 
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normal and tumor samples, indicating in each type the number of samples with at least 1 
read count for lncRNA-OIS1. Interestingly, prostate adenocarcinoma (PRAD) samples 
showed clear lncRNA-OIS1 expression. Using this dataset for differential expression 
analysis, we observed no change between tumor and normal samples (empirical Bayes 
test, B = -5.79, pvalue = 0.28) (Supplementary Table S4), but a significant positive 
correlation between lncRNA-OIS1 and DPP4 expression in the tumor samples (r = 
0.469, pvalue = 2.5e-31) (Figure. 6D), suggesting that at least in PRAD DPP4 expression 
is controlled by lncRNA-OIS1.  
Discussion
Over the past few years, numerous lncRNAs have been discovered and characterized 
as critical factors in physiological and pathological processes. However, the role of 
lncRNAs in oncogene-induced senescence (OIS) remained unexplored. Here, we 
contribute to the understanding of the function of lncRNAs by describing a role of 
lncRNA-OIS1 in cellular senescence provoked by the expression of oncogenic RAS 
(OIS). Upregulation of lncRNA-OIS1 following OIS was required for the induction 
of DPP4, a well-described gene with tumour suppressive activity. Differential gene 
expression analyses of lncRNA-OIS1 knockdown cells indicated attenuated activation 
of CDKN1A following OIS induction, and confirmed changes in cell cycle regulatory 
genes favouring cellular proliferation. Gene complementation experiments indicated 
that DPP4, a lncRNA-OIS1 neighboring  gene, is the downstream target of lncRNA-
OIS1 in senescence. Exactly how DPP4 affects CDKN1A and cell cycle genes, and how 
lncRNA-OIS1 controls DPP4 expression, remains to be uncovered. Nevertheless, we 
describe here an important function of lncRNAs with potentially influential implications 
in cancer biology.  
OIS is a major senescence type and it poses a critical barrier to cancer. A recent study 
shown that the lncRNA-MIR31HG was a senescence modulator during BRAF-V600 
induced senescence in TIG3 cells(46). It has also been shown that loss-of MIR31HG 
reduces cell growth and promotes a strong senescence phenotype through the regulation 
of the tumor suppressor P16INK4A. Here, we add to this knowledge by identifying and 
characterizing the role of lncRNA-OIS1 in regulating senescence through the control of 
a nearby gene DPP4.
Interestingly, we also overexpressed lncRNA-OIS1 in BJ cells to examine whether high 
levels of the lncRNA-OIS1 can drive cells into senescence. However, we neither observed 
senescence-induction nor DPP4 was activated (Supplementary Fig. S7). Additionally, also 
the ectopic expression of lncRNA-OIS1 was not able to revert the bypass of senescence 
and the reduced DPP4 activation induced by lncRNA-OIS1 knockdown under OIS 
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(Supplementary Fig. S8). This is indicative of a cis function of lncRNA-OIS1. Indeed, 
we identified DPP4, a nearby gene to lncRNA-OIS1, as a key component of OIS. First, 
loss-of DPP4, similar to lncRNA-OIS1 loss, resulted in bypass of senescence (Figure. 5). 
Second, ectopic expression of DPP4 reverted the bypass of senescence induced by the 
loss-of lncRNA-OIS1 (Figure. 6A, 6B, 6C and supplementary Fig. S10). Additionally, 
a recent research found that DPP4 can regulate senescence in WI-38 cells, strongly 
supporting our observations(78). However, although both lncRNA-OIS1 and DPP4 
genes reside in the same topologically associating chromatin domain (TAD) through 
a CTCF (CCCTC-binding factor) loop (Supplementary Fig. S12A), and chromatin 
loops can be identified in various ChIA-PET and Hi-C chromatin conformation capture 
datasets (Supplementary Fig. S12B), we did not observe a clear direct interaction of 
lncRNA-OIS1 locus with the promoter of DPP4 using 4C, a chromatin capture analysis 
technique, through two distinct view point sites (Supplementary Fig. S13A). Thus, how 
exactly the expression of DPP4 depends on lncRNA-OIS1 remains unclear. We speculate 
that lncRNA-OIS1 expression may be required to allow high chromatin accessibility 
to senescence-associated DPP4-activating transcription factors by directly recruiting 
essential transcription factors, or alternatively by counteracting chromatin-repressive 
components of the chromatin (Figure. 7). Nevertheless, our findings here elucidate the 
importance of lncRNA-OIS1 for eliciting a proper cellular response to the emergence of 
oncogenic stress. 
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Figure S1. Confirmation of some lncRNAs expression upon RAS induction. 
(A) qRT-PCR expression analysis of seven different lncRNAs in BJ/ET/RasV12 cells treated with 
4-OHT relative to untreated cells.
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Figure S2. Validation of selected lncRNAs. 
(A) Representative images of the BrdU assay of cells under the indicated conditions and after 14 days 
4-OHT treatment. (B) Representative images of the SA-β-gal staining of cells under the indicated 
conditions and after 14 days 4-OHT treatment.
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Figure S3. Validation of additional shRNA vectors. 
(A) Representative images of the BrdU assay of cells under the indicated conditions and after 14 days 
4-OHT treatment. (B) Representative images of the SA-β-gal staining of cells under the indicated 
conditions and after 14 days 4-OHT treatment.
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Figure S4. LncRNA#32 deleted BJ cells have growth advantage during OIS. 
(A) Representative images of cells under the indicated conditions. (B) PCR analysis of genomic DNA 
was used to quantify lncRNA#32 deletion. (C) qRT-PCR analysis of lncRNA#32 in the indicated 
conditions. (D) Sanger sequencing of the PCR fragments obtained in B confirms the deletion of 
lncRNA#32.
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Figure S5. Validation of lncRNA-OIS1 kd in TIG3 cells. 
(A) The proliferation of the various shRNA-transduced TIG3/ET/RASv12 cells was quantified using 
BrdU assay, **P < 0.002, two-tailed Student’s t-test. For every condition, percentage of BrdU-positive 
cells was normalized to negative control cells. (B) Senescent cells were quantified using SA-β-gal 
assay, **P < 0.0005, two-tailed Student’s t-test. For every condition, percentage of β-gal-positive cells 
was normalized to negative control cells. (C, D) Representative images of the BrdU assay and the SA-
β-gal staining of cells under the indicated conditions and after 13 days 4-OHT treatment. (E) qRT–PCR 
analysis of lncRNA-OIS in the various shRNA-transduced TIG3 cells treated with 4-OHT relative to 
untreated cells. Data were normalized to a housekeeping gene and the levels in untreated cells set to 1, 
**P < 0.0005, two-tailed Student’s t-test. 
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Figure S6. Loss-of lncRNA-OIS1 reverses senescence-induced gene expression pattern. 
(A) CDKN1A RNA levels were calculated based on RNA-seq. (B) Quantification of WB results using 
Image J. (C). Selected gene sets that were significantly affected by knocking-down lncRNA-OIS1(for 
all sets shown in this figure, p-value adjusted for multiple testing < 0.05). These sets were identified 
by GSEA analysis comparing gene expression profiles between BJ cells transfected with shRNAs 
against lncRNA-OIS1 and control shRNAs, both in the background of induced oncogenic RAS. GSEA 
comparison between BJ cells with and without induced RAS (senescent vs. control BJ cells) is shown 
in the right column. Knocking-down lncRNA-OIS1 reverse transcriptional signatures that characterize 
OIS.     
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Figure S7. LncRNA-OIS1 overexpression in wild type BJ cells does not affect cell 
proliferation. 
(A) qRT–PCR analysis of lncRNA-OIS1 expression under the indicated conditions. Data were
normalized to a housekeeping gene, and the levels in control cells was set to 1, **P < 0.0001, two-tailed 
Student’s t-test. (B) Proliferation of the cells under indicated conditions was quantified using BrdU
assay. The percentage of BrdU-positive cells was normalized to control cells. (C) Senescent cells were
quantified using SA-β-gal assay. (D) Representative images of the BrdU and SA-β-gal assays. (E) WB
analysis to determine DPP4 protein levels.
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Figure S8. LncRNA-OIS1 overexpression in lncRNA-OIS1kd cells does not affect 
senescence-bypass under RASV12 induction conditions. 
(A) qRT–PCR analysis of lncRNA-OIS1 expression in the indicated conditions. Data were normalized 
to a housekeeping gene, and the levels in control cells were set to 1. **P < 0.0005, two-tailed Student’s 
t-test. (B) Proliferation of the cells under indicated conditions was quantified using BrdU assay. **P 
< 0.001, two-tailed Student’s t-test. The percentage of BrdU-positive cells was normalized to control 
cells. (C) Senescent cells were quantified using SA-β-gal assay. **P < 0.0001, two-tailed Student’s 
t-test. The percentage of SA-β-gal-positive cells was normalized to control cells. (D) Representative 
images of the BrdU and SA-β-gal assays of cells under the indicated conditions. (E) Western blot 
analysis determines DPP4 protein levels.
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Figure S9. LncRNA-OIS1 knockdown in TIG3 cells affects the activation of DPP4 following 
oncogene induction, and loss-of DPP4 shows OIS bypass. 
(A) Screenshots of GRO-seq data of the lncRNA-OIS1 and DPP4 genomic locus in TIG3 cells. (B) 
Screenshots of RNA-seq data of DPP4 and lncRNA-OIS1. (C) qRT–PCR analysis of DPP4 expression 
upon lncRNA-OIS1 kd treated with 4-OHT in BJ cells, **P < 0.002, two-tailed Student’s t-test. (D) 
qRT–PCR analysis of DPP4 expression upon lncRNA-OIS1 kd treated with or without 4-OHT in TIG3 
cells, **P < 0.01, two-tailed Student’s t-test. (E) Representative images of the BrdU assay and β-gal 
staining of cells under indicated conditions.
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Figure S10. Ectopic expression of DPP4 abolishes OIS-bypass induced by lncRNA-OIS1kd. 
(A) Representative images of the BrdU assay of cells under the indicated conditions and after 14 
days of 4-OHT treatment. (B) Representative images of SA-β-gal staining of cells under the indicated 
conditions and after 14 days of 4-OHT treatment. (C) Quantification of western blot pictures by Image J.
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Figure S11. LncRNA-OIS1 expression is extremely low in most tumors. 
(A) TCGA data analysis of lncRNA-OIS1. We plotted the read counts of lncRNA-OIS1 in normal 
and tumor samples. Indicated in each tumor type the number of samples with at least 1 read count for 
lncRNA-OIS1. Of all 33 TCGA tumor types only those with at least 5 normal and 5 tumor samples are 
shown.
2LncRNA-OIS1 regulates DPP4 activation to modulate senescence induced by RAS
65
A
B
CTCF CHIA-PET MCF7
POL II CHIA-PET MCF7
POL II CHIA-PET K562
HiC HeLa
Figure S12. LncRNA-OIS1 and DPP4 are in the same topological associated chromatin 
domain. 
(A) Screenshot of CTCF CHIA-PET data in MCF7 cells. (B) Screenshot of RNA Polymerase II (POL-
II) CHIA-PET data in MCF7, K562 cells, and HI-C data of Hela cells.
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LncNRA-OIS1
A
Figure S13. LncRNA-OIS1 does not have direct interaction with DPP4 promoter. 
(A) 4C experiments do not detect direct interaction between lncRNA-OIS1 locus and DPP4 promoter.
We used two different viewpoints, with or without RASV12 induction. Nevertheless, this data confirms
that lncRNA-OIS1 and DPP4 are in the same TAD.

3
Ruiqi Han1,3,5, Li Li1,3,5, Alejandro Piñeiro Ugalde1, Arieh Tal1, Zohar Manber4, 
Eric Pinto Barbera1,3, Veronica Della Chiara1, Ran Elkon4,6, Reuven Agami1,2,3,6
1Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
2Department of Genetics, Erasmus University Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
3Oncode Institute, Amsterdam, The Netherlands.
4Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, 
 Tel Aviv, Israel
5These authors contributed equally
6Co-corresponding authors
Genome Biology. 2018
Functional CRISPR screen 
identifies AP1-associated enhancer 
regulating FOXF1 to modulate 
oncogene-induced senescence
Chapter 3
Chapter 3
70
Abstract
Background
Functional characterization of noncoding elements in the human genome is a major 
genomic challenge, and the maturation of genome-editing technologies is revolutionizing 
our ability to achieve this task. Oncogene-induced senescence (OIS), a cellular state of 
irreversible proliferation arrest that is enforced following excessive oncogenic activity, 
is a major barrier against cancer transformation, and therefore bypassing OIS is a critical 
step in tumorigenesis. Here, we aimed at further identification of enhancer elements that 
are required for the establishment of OIS.
Results
We first applied genome-wide profiling of enhancer-RNAs (eRNAs) to systematically 
identify enhancers that are activated upon oncogenic stress. DNA motif analysis of these 
enhancers indicated AP-1 as a major regulator of the transcriptional program induced by 
OIS. We thus constructed a CRISPR-Cas9 sgRNA library designed to target OIS-induced 
enhancers that are putatively regulated by AP-1, and used it in a functional screen. We 
identified a critical enhancer that we dub EnhAP1-OIS1 and validated that mutating the 
AP-1 binding site within this element results in OIS bypass. Furthermore, we identified 
FOXF1 as the gene regulated by this enhancer, and demonstrated that this target gene 
mediates EnhAP1-OIS1 effect on the senescence phenotype.
Conclusion
Our study elucidates a novel cascade mediated by AP-1 and FOXF1 that regulates OIS 
and further demonstrates the power of CRISPR-based functional genomic screens in 
deciphering the function of noncoding regulatory elements in the genome.
Keywords
CRISPR – Functional screen – Enhancers – Oncogene-induced senescence - Gene 
regulation – AP1- FOS – JUN – FOXF1
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Background
Over the last decade, large-scale genomic projects identified hundreds of thousands of 
regulatory elements in the human genome, most of them are putative enhancers(1,2). 
Identification of candidate enhancer regions was mainly based on profiling of 
characteristic histone modifications (e.g., H3K27ac and H3K4me1) and binding of 
transcriptional activators (e.g., p300). Recently, eRNA expression, typically transcribed 
bi-directionally at promoter-distal cis-regulatory elements, was indicated as a sharp 
feature of active enhancers, and was utilized for systematic discovery of enhancers 
across the genome(3). Importantly, changes in eRNA production correlate with changes 
in the enhancer activity(4,5). Yet, functional characterization of the plethora of candidate 
enhancer elements is a major genomic challenge(6). High-throughput reporter assays to 
probe the functions of regulatory regions were developed in recent years(7). However, 
these methods separate putative regulatory elements from their native chromosome, 
so that any effect of chromatin context and long range regulatory interactions is lost. 
Furthermore, definitive demonstration of the function of regulatory element requires 
their perturbation in situ. The maturation of novel genome-editing technologies is 
revolutionizing our ability to interrogate the function of the noncoding genome. This 
potential was demonstrated by pioneering CRISPR-based functional genomic screens 
that systematically targeted noncoding elements in the human genome(8–11).
In one of these CRISPR-based functional genomic screens we focused on oncogene-
induced senescence (OIS), which is a cellular state of irreversible proliferation arrest 
that is enforced in face of excessive oncogenic activity (oncogenic stress) (8). OIS is a 
major barrier against cancer transformation (12,13) and therefore overcoming OIS is a 
critical step in tumorigenesis (14). Activation of this process is largely dependent on p53 
(13,15), and consequently its bypass by cancer cells is mainly achieved by emergence 
of somatic mutations in p53 or other components of its pathway (16,17). As p53 is an 
enhancer binding transcription factor (TF), whose function in transcriptional regulation 
is required for its tumor suppressive activity, we previously performed a CRISPR-
based functional genomic screen that systematically targeted p53-bound enhancers(18). 
That screen uncovered several p53-bound regulatory elements that are required for the 
activation of OIS. However, aberrant expression of oncogenes can lead to activation of 
additional transcription factors (TFs) whose function is also critical for the establishment 
and/or maintenance of OIS. In the current study, we aimed at the identification of such 
TFs and discovery of additional enhancers that are required for the establishment of 
OIS. We carried out an unbiased profiling of enhancers activated upon oncogenic stress, 
which indicated AP-1 as a major regulator of the transcriptional program induced by 
OIS. We thus generated a CRISPR-Cas9 sgRNA library designed to target enhancers 
putatively regulated by AP-1, and used it in a functional screen to identify those required 
for OIS. This screen detected EnhAP1-OIS1, an AP-1 bound enhancer that is hyper-activated 
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in OIS and whose abrogation results in OIS bypass. Furthermore, we identified FOXF1 
as the target gene of this enhancer, and demonstrated that it regulates the senescence 
phenotype.
Material and methods 
Cell culture
BJ/ET/RasV12and HEK293-T cells were cultured in DMEM medium (Gibco), 
supplemented with 1% penicillin/streptomycin (Gibco) and 10% FCS (Hyclone). To 
induce OIS, BJ cells were treated with 100 nM 4-OHT (Sigma) for 14days.
Analysis of GRO-seq data
GRO-seq was applied to control and RASG12V-induced hTERT immortalized BJ cells (14 
days after RAS induction). These conditions were probed using biological duplicates. 
Sequenced reads were aligned to the human genome (hg19) using bowtie2 (43). 
Transcriptional units (TUs) were inferred from the GRO-seq data using HOMER (44). 
Read counts per TU were calculated using HTseq-count (45). 76,200 TUs covered by 
at least 20 reads in at least one sample were detected. TU expression levels were than 
normalized using quantile normalization to allow comparison between samples, and 
fold-change (FC; presented in log2 base) were calculated between the RAS-induced 
and control samples. To avoid inflation of high FC value for lowly expressed TUs, we 
set a floor value of 10 (that is, all expression levels below 10 were set to 10). Next, we 
defined bi-directional TUs as TUs whose start site is separated by no more than 800 bp 
and are transcribed on opposite strands (TU+ and TU-). As bi-directional transcription 
is a hallmark of transcriptional regulatory elements, we refer to these loci as regulatory 
elements (REs). Overall, this analysis defined 36,497 regulatory elements. Last, a 
regulatory element (bi-directional TU) was defined as OIS-induced if the expression 
level of both its mates was elevated by at least 2-folds upon RAS induction, in both 
duplicates. In total, 1,821 OIS-induced REs were identified in our dataset (Table S1).
Motif enrichment analysis
The sequences of the OIS-induced regulatory elements were searched for statistically 
over-represented TF binding motifs. We performed this de novo motif analysis using 
DREME (46). For each bi-directional TUs, we scanned the region between the start 
site of the opposite mates (TU+ and TU-) plus a margin of 200 bp to each direction. As 
control sequences, we extracted adjacent sequences of the same length are immediately 
upstream and downstream the test sequence. The binding motif of JUN/FOS was highly 
enriched (p=1.2*10-88) on the OIS-induced REs. Specific occurrences of the enriched 
JUN/FOS motif were identified using FIMO with default parameters (47). Overall, 762 
JUN/FOS motif occurrences were found on 638 OIS-induced REs.
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CRISPR library construction and analysis
We designed a CRISPR library to target the FOS/JUN motifs in the OIS-induced REs. 
For 398 of the 638 OIS-induced REs with FOS/JUN motif, we found an occurrence of the 
NGG PAM in a location that is expected to induce a Cas9 DNA cleavage within a margin 
of 5 bp with respect to the motif (that is, the cut is expected to occur within the motif 
or up to 5 bp from its edges). Overall, we designed 840 distinct sgRNAs, collectively 
targeting FOS/JUN motif in 398 OIS-induced REs. We cloned these sgRNAs into 
pLentiCRISPRv2 vector and generated a plasmid library (which we call CRISPR-AP1-
EnhLib). Induced and control BJ-indRASG12V were transduced with four independent 
lentiviral pools of CRISPR-AP1-EnhLib. Following four weeks of culturing, we harvested 
library-transduced cells, isolated genomic DNA, amplified integrated vectors by PCR, 
and used next-generation sequencing (NGS) to quantify the abundance of integrated 
sgRNAs present in each population. Read counts were normalized to 1M reads and 
enrichment ratio (fold-change in log2) were calculated for each sgRNA between the 
induced and control samples per replicate. (To avoid inflation of FC for sgRNAs covered 
by low number of reads, counts bellow 50 were set to 50). Next, average enrichment 
factor was calculated per sgRNA over the four replicates and was transformed to a Z 
score (Fig. 2B, Table S3).
Senescence-associated b-galactosidase assay
BJ cells were transduced with different sgRNA constructs and selected with puromycin. 
After selection, cells were seeded in triplicate in 6-well plates and treated with 100 
nM 4-OHT for 14 days. β-galactosidase measurement was performed by following the 
protocol of the Senescence β-Galactosidase Staining Kit (Cell Signaling), and at least 
1000 cells were analyzed for each condition.
BrdU proliferation assay
BJ cells were seeded in 6-well plates on day 1. Next morning, cells were incubated in 
fresh medium for 3 h with 30 µM bromodeoxyuridine (BrdU, Sigma) followed by two 
times PBS wash and then fixed with 4% formaldehyde. Cells were washed two times 
with PBS and treated with 5M HCl/0.5% Triton to denature DNA. Cells were neutralized 
with 0.1M Na2B4O7. The cells were then treated with blocking buffer (3% BSA in 0.5% 
Tween PBS) for 30min and incubated with anti-BrdU antibody (Dako) with blocking 
buffer for 2 hours at room temperature. Cells were washed with PBS three times, and 
finally incubated with FITC-conjugated anti-mouse Alexa Fluor 488 secondary antibody 
(Dako) in blocking buffer for 1 hour, washed three times, stained with propidium iodide 
for 30min. BrdU incorporation was measured by immunofluorescence (at least 1000 
cells were scored for each condition). The numbers of individual nucleus and BrdU-
stained nucleus were counted using imageJ software.
Chapter 3
74
Luciferase reporter assay
The constructs with the enhancers were cloned based on pGL3-promoter (Promega) 
vector. The enhancer region was PCR amplified from BJ genomic DNA and inserted 
downstream of the firefly luciferase reporter gene. The transfection was performed by 
seeding 1x105 of cultured cells in 6-well plates. The next day, 500ng of each construct 
(pGL3-promoter, pGL3-EnhAP1-OIS1-Fw, and pGL3-EnhAP1-OIS1-Rv) were co-transfected 
with 50ng of Renilla luciferase reporter construct using Fugene-6 (Promega) following 
manufacturer’s protocol. Luciferase reporter assay was performed 24h post transfection 
using Dual-Luciferase Reporter assay kit (Promega). Cells were lysed directly on the 
plate with passive lysis buffer for 15min at room temperature. Firefly and Renilla 
luciferase activity was measured with the substrates from the kit using Centro XS3 
LB960 machine (Berthold technologies). For BJ-indRASG12V, cells were pre-treated with 
100nM 4-OHT for 48h prior transfection. For HCT116, cells were treated with UV-C 
(50J/m2) or MG132 (5µM) 18h after transfection. The luciferase assay was performed 
5h post treatment.
Mutagenesis of EnhAP1-OIS1
Mutations of EnhAP1-OIS1 were performed using QuikChange Lightning site-directed 
mutagenesis kit (Agilent) according to the manufacture’s manual. Briefly, primers for 
mutagenesis were designed using the online tool from Agilent. pGL3-EnhAP1-OIS1-Fw and 
pGL3-EnhAP1-OIS1-Rv were PCR amplified and transformed into DH5α bacteria. Single 
colonies from each mutant were sequence verified and used for transfection.
RNA isolation, reverse transcription and qRT-PCR
Total RNA was extracted by using TRIsure (Bioline) reagent and following the 
manufacturer’s protocol. Reverse transcription was done with SuperScript III 
(Invitrogen) using 1 µg of total RNA per reaction. qRT-PCR reaction was performed 
using SensiFAST SYBR No-ROX Kit (Bioline) in LightCycler 480 (Roche). Primers 
used are listed in Table S4.
Western blot
1x106 Cells were seeded in 10cm dish and treated with DMSO or 4-OHT for 14 days. 
Cells were trypsinized and cell pellets were lysed with RIPA buffer supplemented with 
1x cOmplete protease inhibitor cocktail (Roche) following the manufacturer’s protocol. 
Protein concentrations were determined using Pierce BCA protein assay kit (Thermo 
Scientific). Lysates were separated on SDS-PAGE gels and transferred Membranes 
were immunoblotted with the following antibodies: CDKN1A (Sc-397, Santa Cruz; 1: 
1,000), HRAS (C-20, Santa Cruz; 1: 1,000), FoxF1 (ab168383, Abcam, 1:1000), HSP90 
(610418, BD biosciences, 1:3000). Protein bands were visualized using corresponding 
secondary antibodies (Dako) and ECL reagent (GE Healthcare).
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Lentiviruses production and infection
HEK293T cells were seeded at the density of 5 X 106 cells per 10cm dish one day prior 
transfection. Transfection was performed using PEI (Polyethylenimine, Polysciences) 
and medium was refreshed after 16h. Virus-containing supernatant was collected 48h 
post transfection by filtering through a 0.45 µm membrane (Milipore Steriflip HV/
PVDF) and snap-frozen, stored at −80°C. BJ cells were infected and selected with the 
proper antibiotics 48 h after transduction for at least 4 days until no surviving cells 
remained in the no-transduction control plate.
Chromatin Conformation Capture (3C) analysis
10 x 106 cells were harvested in PBS for each 3C sample. Cells were centrifuged at 
300xg for 5min at RT, and resuspended PBS / 10% FBS. Then cells were incubated with 
equal volume of 4% formaldehyde (2% end concentration) for 10min and quenched 
with 2M glycine solution (0.2M end concentration), followed by centrifugation at 300xg 
for 5min at 4oC. Cell pellet was then resuspended in PBS / 10% PBS and centrifuged at 
300xg for 5min at 4oC. The supernatant was then discarded and snap-frozen, stored at 
-80oC. The cell pellet was lysed in 3mL lysis buffer (50mM Tris -HCl pH 7.5, 0.5% NP-
40, 1% Triton X-100, 150mM NaCl, 5mM EDTA, protease inhibitor cocktail (Roche)) 
for 1.5h at 4oC, followed by centrifugation at 1000xg for 3min. The pellet was washed 
once in 1.2x restriction buffer and resuspended again in 500µL of 1.2x restriction buffer. 
15µL of 10% SDS was added to the suspension and incubated at 37oC while shaking 
at 400rpm. 75µL of 20% Triton X-100 was added to the suspension and incubated at 
37oC while shaking at 400rpm. The samples were then centrifuged at 1000 x g for 3min 
and resuspended in 500µL of 1x restriction buffer. The digestion was performed with 
addition of 200U of Csp6I (Thermo Fisher Scientific) at 37oC overnight. The digestion 
efficiency was assessed the next day on agarose gel. The enzyme was then inactivated 
at 65oC for 20min and then samples were centrifuged at 1000 x g for 3min to remove 
the restriction buffer. The pellet was resuspended in 7mL of 1x ligation buffer, and the 
ligation was performed with addition of 50U of T4 DNA ligase at 16oC overnight. Again, 
the ligation efficiency was examined on agarose gel. De-crosslinking was performed by 
addition of 30µL of protease K (Roche) at 65oC overnight. To remove residual RNA, 
15µL of RNaseA cocktail (Ambion) was added to the samples and incubated at 37oC 
for 45min. DNA was recovered by adding 7mL of isopropanol and 70µL of NucleoMag 
96 PCR beads (Bioke) and incubated for 30min at room temperature. The samples 
were centrifuged for 3min at 1000 x g and washed with 80% ethanol twice. Finally, the 
beads were dried and eluted in 300µL of 10mM Tris-HCl pH 7.5. To assess the physical 
interactions between EnhAP1-OIS1 and target regions, we designed a constant primer (C1) 
that amplify the EnhAP1-OIS1 region overlapping the junction created by Csp6I enzyme. 
For each assessed region, we designed two primers (reverse and forward) to examine 
the interactions with EnhAP1-OIS1. The first PCR was performed with primer C1 and each 
candidate primer for 25 cycles. Afterwards, a nested PCR was performed using a second 
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constant primer (C2) and each candidate primer for another 18 cycles. Finally, PCR 
products were resolved on 2% agarose gel. To assess the primer efficiency, we PCR 
amplified the genomic regions of EnhAP1-OIS1 and FOXF1, and mixed equal molar of 
each fragments as the template. The template DNA was then digested and ligated as 
mentioned. Finally, the quantifications were normalized with the primer efficiencies. To 
examine the sequences of the PCR products, DNA bands were cut, isolated, and sanger-
sequenced. 
Mutation analysis of enhancer regions
Genomic DNA of the cells transduced with sgRNAs were isolated and quantified. 500ng 
of the genomic DNA was used for PCR to amplify the enhancer region. We performed a 
two-step PCR by introducing the P5 adapter sequences in the first PCR and P7 adapters 
with the indexes in the second PCR. After the second PCR, the libraries were purified 
with CleanPCR beads (CleanNA) and quantified on 2100 Bioanalyzer using a 7500 
chip (Agilent). Equimolar of each sample was taken for the final library. Libraries were 
sequenced using the Mi-Seq platform. Sequenced reads were aligned to the amplified 
enhancer region using bowtie. Bam files were analysed to count the number of mutations 
(mismatches, insertions or deletions) identified at each location in that region.
RNA-seq library construction
Total RNA was isolated using Trisure reagent (Bioline) following the manufacturer’s 
protocol. Briefly, cells were lysed in Trisure, precipitated with isopropanol, and dissolved 
in RNase-free water. To generate strand-specific libraries, we used the TruSeq Stranded 
mRNA sample preparation kit (Illumina) following the manufacturer’s instructions. 
Briefly, 1000ng of total RNA was polyA-enriched using oligo-dT beads, and the RNA 
was fragmented, random primed and reverse transcribed using SuperScript II Reverse 
Transcriptase (Invitrogen). Second strand cDNA was then synthesized, 3’-adenylated 
and ligated to Illumina sequencing adapters and subsequently amplified by 12 cycles of 
PCR. The sequencing libraries were analyzed on a 2100 Bioanalyzer using a 7500 chip 
(Agilent), and pooled equimolar into a 10nM multiplex sequencing pool.
Sequencing
Sequencing of the CRISPR screen and RNA-seq was done using single reads of 65bp 
on the Hi-Seq2500 platform (Illumina). Mutation analysis of enhancer regions were 
performed with single reads of 150bp on the Mi-Seq system with Mi-Seq reagent v2 
Nano kit.
RNA-seq analysis
Gene expression profiles were recorded in BJ-indRASG12V (14 days after RAS induction 
by 4-OHT treatment) transduced with CRISPR vectors that either targeted the EnhAP1-
OIS1 using sgRNA-AP169, sgRNA-AP171, targeted FOXF1 itself or transduced with a 
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control non-targeting sgRNA (sgRNA-NT). Sequenced reads were aligned to the human 
genome (hg19) using TopHat2 (48). Number of reads mapped to each annotated gene 
was counted using HTseq-count (45), and then converted to RPKMs (using GENCODE 
v25 annotations). RPKM levels were further normalized using quantile normalization 
and expression levels in each sample relative to the control non-targeting sample were 
calculated (in log2 base). Biological pathways and processes affected by targeting the 
EnhAP1-OIS1 or FOXF1 were sought using gene-set enrichment analysis (GSEA) (23).
Results 
Genome-wide identification of OIS-induced enhancers
We previously carried out a CRISPR-based screen aimed at identification of p53-bound 
enhancers that are required for OIS(17). That screen was confined to regions that are 
directly bound by p53 as detected by p53 ChIP-seq analysis, and therefore missed 
enhancers that are critical for OIS enforcement and are regulated by other TFs, in either 
p53-dependent or independent manner. To overcome this limitation and to globally 
screen DNA regulatory elements activated by OIS without being biased by preselection 
of a candidate TF, we first sought to comprehensively detect all the enhancers that are 
activated upon oncogenic stress. To this goal we utilized Global Run-On sequencing 
(GRO-seq), a nascent RNA detection method (19), that allow robust determination of 
eRNA expression, as a quantitative measure for enhancer activity (7,8,18). We used a 
cellular system in which the oncogene RASG12V was induced in hTERT-immortalized 
BJ cells (BJ-indRASG12V). As these cells contain wild-type p53, oncogenic stress 
results in a very potent activation of OIS and proliferation arrest (20). Exploiting bi-
directional transcription as a hallmark of transcriptional activity at enhancers and 
promoters (7,21,22), we detected 1,821 regulatory elements whose activity was induced 
in BJ-indRASG12V upon oncogene induction for 14 days (Fig. 1A; Table S1). Next, we 
bioinformatically searched for TFs that potentially mediate the activation of these regions 
by performing de novo DNA motif enrichment analysis. Remarkably, we found that the 
regulatory regions activated during the induction of OIS were significantly enriched for 
the binding motif of the AP1 (FOS:JUN) transcription factor (TF)  (Fig. 1B). Overall, 
these results suggest an important role for AP1 in the regulation of the transcriptional 
response to oncogenic stress.
Therefore, we constructed a CRISPR library that systematically targets OIS-induced 
DNA elements that are putatively regulated by AP1, and performed a functional genetic 
screen to identify those that are required for OIS activation. The de novo motif analysis 
detected 762 AP1 motifs in 638 OIS-induced regulatory elements (over-representation 
p-value=1.2*10-88). We examined which of these motif occurrences can be targeted by 
CRISPR-Cas9, given the requirement for the presence of the NGG PAM motif near the 
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AP-1 motif. WE required that the Cas9-madiated DNA cut will occur either within the 
motif itself or up to a margin of 5 nt with respect to it (Fig. 1C). 398 (62%) of the 638 
OIS-induced regulatory elements (REs) containing AP1 motif met this criterion, with 
most motifs targeted by 2-3 distinct sgRNAs. Accordingly, we designed 840 sgRNAs 
that target AP1 motifs in 398 OIS-induced regulatory elements. We cloned these sgRNAs 
as a pool into pLentiCRISPRv2 vector, and generated a plasmid library referred herein as 
CRISPR-AP1-EnhLib (Fig. 1D and Table S2).
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Figure 1. Design of a CRISPR screen targeting AP1 enhancers which are activated upon 
oncogenic stress. 
A. An example of an enhancer whose activity is induced in response to oncogenic stress. Enhancer 
activity is inferred from the typical bi-directional transcription of eRNAs (BJ+DMSO indicates 
proliferating cells, and BJ+4-OHT indicates senescent cells); Genomic regions that show DNase 
hypersensitivity (DHS), as determined by ENCODE, are shown by the grey track). Overall, our GRO-
seq analysis identified 1,821 regulatory elements (REs; enhancers or promoters) whose activity was 
induced in BJ cells in face of RAS activation. B. De novo motif analysis detected highly significant 
enrichment of the FOS:JUN (AP1) DNA motif in the regulatory elements that were induced upon 
oncogenic stress. Top – the enriched motif detected in our dataset; bottom – the AP1 motif from the 
JASPAR DB (49). C. An example for occurrence of an AP1 motif within an enhancer that was induced 
upon oncogenic stress, that is located close enough to an NGG PAM motif, resulting in Cas9-mediated 
DNA cleavage that occur within the motif (Cas9 cleavage occurs ~3 nt before the PAM). Overall, we 
identified 398 induced REs with AP1 motif that met this requirement (Cas9 cleavage within a margin 
of 5 nt with respect to the motif). D. Statistical summary of the CRISPR-AP1-EnhLib used in our 
functional screen.
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CRISPR screen targeting OIS-induced enhancers with AP-1 motif
We used the CRISPR-AP1-EnhLib library to screen for DNA elements that are putatively 
regulated by AP1 and are required for the activation of OIS. BJ-indRASG12V were 
transduced with four independent lentiviral pools of CRISPR-AP1-EnhLib and selected 
with puromycin. Then we treated the cells with 4-OHT (RAS induction) or DMSO 
(control) as shown in Figure 2A. Following four weeks of culturing, we harvested the 
cells, isolated genomic DNA, amplified integrated vectors by PCR, and used next-
generation sequencing (NGS) to quantify the abundance of integrated sgRNAs present 
in each population. We reasoned that sgRNAs targeting regulatory elements that are 
required for OIS would cause bypass of senescence, sustained cell proliferation, and 
thus would be enriched in the cell population under oncogenic stress compared to control 
(Fig. 2A). Indeed, our screen detected several sgRNAs that were highly enriched in the 
OIS population (Fig. 2B; Table S3), among them, five showed an average enrichment 
fold above 1.75 over the four replicates of the screen. Notably, two of these five sgRNAs, 
sgRNAs-AP169 and sgRNA-AP171, are independent sgRNAs that target the same 
enhancer region (Fig. 2B), hence increasing the confidence that these are true positive 
hits. ENCODE ChIP-seq data confirmed a strong binding of both FOS and JUN to this 
region (Figure S1). Moreover, our GRO-seq data showed ~2-fold induction of eRNA 
expression from this enhancer in response to oncogenic stress. Thus, we selected this 
regulatory region for further validation and functional characterization and named it 
EnhAP1-OIS1.
First, using individual transductions, we validated that the introduction of sgRNAs AP169 
and AP171 to BJ-indRASG12V cells causes a potent bypass of OIS, as judged by cell number 
and morphology (Fig. 2C). Second, we confirmed that introduction of these two sgRNAs 
to BJ-indRASG12V cells indeed results in an array of small deletions and insertions at the 
expected position within the AP1 binding motif in the targeted enhancer (Figure S2). 
Third, following induction of oncogenic stress, sgRNAs AP169 and AP171 transduced 
BJ-indRASG12V cells showed a significant reduction in senescent-associated-β-Gal (SA-
β-Gal) staining (Fig. 2D, Figure S3) and an elevated BrdU staining (Fig. 2E, Figure 
S3), indicative of attenuated activation of cellular senescence and of sustained cellular 
proliferation compared to the NT control. As expected, while the effect caused by these 
two sgRNAs was highly significant, it was not as strong as the effect elicited by targeting 
p53 (Fig. 2D-E). Last, we examined the activity of EnhAP1-OIS1 following the transduction 
of sgRNAs AP169 and AP171 by measuring eRNA expression at the EnhAP1-OIS1 locus. 
As expected, targeting EnhAP1-OIS1 by these two sgRNAs significantly compromised its 
activity during OIS compared to the control sgRNA (Fig. 2F).
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Figure 2. Functional CRISPR screen discover a novel enhancer required for OIS. 
A. Schematic representation of the set-up of our functional screen. B. Results of the CRISPR screen. 
sgRNAs are sorted by the enrichment score based on the ratio between their prevalence in the BJ+4-
OHT and BJ +DMSO control populations (measured 4 weeks after 4-OHT treatment). Y-axis shows 
Z scores of the mean sgRNA enrichment scores (calculated over the four replicates of the screen). 
Coloured in red are two sgRNAs, sgRNA-AP169 and sgRNA-AP171, that target the same enhancer, 
called here EnhAP1-OIS1 C. Individual transductions of sgRNA- AP169 and sgRNA-AP171 validated that 
they cause OIS bypass. sgRNA targeting p53 was used as a positive control and a non-targeting (NT) 
sgRNA was used as a negative control. D. Targeting EnhAP1-OIS1 by either sgRNA- AP169 or sgRNA-
AP171 caused OIS bypass as measured by β-gal staining, a canonical mark for senescence (p53ko used 
as a positive control). Data shown represents mean (SD), n=4. *p<0.05. E. Targeting EnhAP1-OIS1 by 
either sgRNA- AP169 or sgRNA-AP171 resulted in enhanced proliferation as measured by BrdU staining 
(p53ko used as a positive control). Data shown represents mean (SD), n=4. *p<0.05. F. Measurement 
of eRNA production at EnhAP1-OIS1 in cells with the indicated sgRNAs. eRNA levels are significantly 
decreased upon mutagenesis of the AP1 binding site caused by either sgRNA- AP169 or sgRNA-AP171. 
Data shown represents mean (SD), n=3. *p<0.05. G. BJ-indRASG12V cells were transfected with 
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the indicated plasmids, and treated with DMSO or 4-OHT for 72h. pGL3 constructs contain firefly 
luciferase reporter gene with the corresponding enhancer (none for pGL3-promoter, two different 
orientations for EnhAP1-OIS1). Relative luciferase activity is calculated by dividing the firefly luciferase 
activity to that of Renilla luciferase. Normalized luciferase activity is calculated by dividing the relative 
luciferase activity to that of pGL3-promoter for each condition. Data shown represents mean (SD), n=6. 
*p<0.05. H. BJ-indRASG12V cells were transfected with the indicated enhancer constructs. Endogenous 
motif represents the original sequence of EnhAP1-OIS1, in vitro mutation construct represents mutagenesis 
of the AP1 consensus motif, and MU44835851 represents mutant construct bearing a C>A mutation as 
indicated. The cells were treated with 4-OHT for 48h prior transfections. Data shown represents mean 
(SD), n=3. *p<0.05.
Next, we carried out in vitro reporter assays to verify that EnhAP1-OIS1 functions as 
enhancer and promotes transcription of target genes. We cloned EnhAP1-OIS1 downstream 
of the Firefly luciferase gene in two orientations in pGL3-promoter vector followed by 
transfection into BJ-indRASG12V cells. While we did not observe a noticeable elevation of 
luciferase activity in cells treated with DMSO, there was a significant increase of 3-fold 
in cells treated with 4-OHT (Fig. 2G). To verify that mutations in the AP1 binding site 
disrupts the enhancer activity as we observed in sgRNA-AP169/71 cells, we mutated the 
AP1 motif of EnhAP1-OIS1 and examined the effect on the enhancer activity, in condition 
of oncogenic stress. Indeed, the mutations completely abolished the ability of EnhAP1-OIS1 
to stimulate luciferase expression (Fig. 2H).  In addition, we searched for tumor somatic 
mutations within the AP1 binding motif (using ICGC data), and found one case in a lung 
cancer patient (Figure S4). The mutation is a C to A substitution within the consensus 
motif of AP1, and located at the cut site of sgRNA-AP169. To examine if this somatic 
mutation disrupts the activity of EnhAP1-OIS1, we performed mutagenesis of EnhAP1-OIS1 on 
the reporter construct with a single nucleotide substitution. Remarkably, we observed 
a 50% reduction of the enhanced luciferase activity (Fig. 2H), suggesting an important 
role of the specified nucleotide in determining binding affinity of AP1 to this enhancer. 
Taken together, our functional genetic screen and subsequent focused experiments have 
identified and validated a novel AP1-bound enhancer whose activity is required for 
proper induction of OIS.
FoxF1 is a target gene of EnhAP1-OIS1
Next, we set up experiments to elucidate the mode of action by which EnhAP1-OIS1 is 
required for OIS. Enhancers regulate gene expression of cis-located target genes that can 
reside hundreds of kbp away. Examination of our GRO-seq data indicated that FOXF1, 
the nearest gene to the EnhAP1-OIS1 locus (located >100 kbp downstream of it), was ~2 
fold induced following oncogenic stress (Fig. 3A), suggesting a potential functional 
connection. No other gene in a 1 Mbp distance from EnhAP1-OIS1 showed such a strong 
effect. Furthermore, we performed RNA-seq with cells transduced with sgRNA-AP169 
and sgRNA-AP171, and observed a significant reduction in the expression of FOXF1 
(Figure S5). We validated this result using qRT-PCR analysis, which also indicated that 
targeting EnhAP1-OIS1 by either sgRNA-AP169 or sgRNA-AP171 results in a significant 
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Figure 3. FOXF1 is the target gene regulated by EnhAP1-OIS1.  
A. UCSC screenshot of GRO-seq analysis of BJ-indRASG12V cells. BJ cells were treated with DMSO 
or 4-OHT for 14 days. Bidirectional transcription is represented by using positive and negative values 
for expression in the Crick and Watson strands, respectively. The genomic regions of EnhAP1-OIS1 and 
FOXF1 are enlarged. Note the enhancement in GRO-seq signal for both EnhAP1-OIS1 and FOXF1 in 
BJ+4-OHT (brown track) compared to BJ+DMSO (blue track). B. mRNA levels of FOXF1 are reduced 
in sgRNA-AP169 and sgRNA-AP171 targeted cells under 4-OHT treatment. Data shown represents mean 
(SD), n=3. *p<0.05. C. BJ-indRASG12V cells transduced with the specified sgRNAs were treated with 
DMSO or 4-OHT for 14 days, and FOXF1, p21, and HRas protein levels were measured by western 
blot. HSP90 was used as the loading control. The band of FOXF1 is marked with an arrow. ER-HRas 
indicates the induced version of HRas. D. Targeting the FOXF1 and p53 genes caused OIS bypass as 
measured by β-gal staining. Note the stronger effect of FOXF1ko compared to the effect elicited by 
targeting EnhAP1-OIS1  (Fig. 2D). Data shown represents mean (SD), n=4. *p<0.05. E. Targeting FOXF1 
and p53 gene resulted in enhanced proliferation as measured by BrdU staining. Data shown represents 
mean (SD), n=4. *p<0.05.
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reduction in the expression level of FOXF1 under OIS conditions (Fig. 3B). Western 
blotting analysis confirmed this result at the protein level, in addition to confirming 
that FOXF1 expression is increased following oncogenic stress (Fig. 3C). Publicly 
available RNA Pol II ChIA-PET data (from Hela cells) indicate physical interaction 
between EnhAP1-OIS1 and the 3’ region of FOXF1 (Figure S6), which was confirmed in 
the chromatin conformation capture (3C) experiments of senescent BJ cells (Figure S7). 
More importantly, the physical interactions between EnhAP1-OIS1 and the promoter region 
of FOXF1 were significantly stronger (Figure S7), suggesting a robust transcriptional 
regulation of EnhAP1-OIS1. Collectively, these results strongly point to FOXF1 as the target 
gene of EnhAP1-OIS1.
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Figure 4. EnhAP1-OIS1 and FOXF1 knockouts display expression profiles of senescence bypass. 
GSEA analysis of expression profiles measured in 4OHT-treated BJ-indRASG12V cells targeted by 
sgRNA-AP169, sgRNA-AP171, or sgRNA-FOXF1 compared to the profile of control 4OH-treated cells 
transduced with non-targeting sgRNA. A list of shared genes within each group is shown. 
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Loss of FOXF1 causes senescence bypass and abolishes senescence 
expression signatures
To further establish FOXF1 as the target gene that links EnhAP1-OIS1 to senescence, we 
examined the phenotypic effect of knocking out FOXF1. Indeed, targeting FOXF1 
results in a strong senescence bypass phenotype, as evident by significant reduction 
in SA-β-Gal staining (Fig. 3D) and elevated BrdU staining (Fig. 3E), similar to the 
effect elicited by targeting EnhAP1-OIS1 (Fig. 2E-F). Effective FOXF1 knockout was 
confirmed by western blotting analysis (Fig. 3C). Last, we used RNA-seq to globally 
compare expression profiles in BJ-indRASG12V cells transduced with either sgRNAs 
targeting EnhAP1-OIS1 (sgRNA-AP169 or sgRNA-AP171), sgRNA targeting FOXF1, or a 
control non-targeting sgRNA. Gene-set enrichment analysis (GSEA) (23) for functional 
characterization of the biological processes affected by these genetic manipulations 
showed that cell-cycle genes and genes encoding ribosomal proteins are significantly up-
regulated when targeting either EnhAP1-OIS1 or FOXF1, reflecting the bypass of OIS and 
the subsequent enhanced proliferation experienced by these cells following oncogene 
hyperactivity (Fig. 4). Conversely, the induction of various extra cellular matrix (ECM) 
components that is exhibited in OIS was largely attenuated in cells with EnhAP1-OIS1 or 
FOXF1 knockouts (Fig. 4). Taken together, our results strongly indicate that EnhAP1- OIS1 
controls OIS through the regulation of FOXF1 expression (Fig. 5).
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Figure 5. Model of EnhAP1-OIS1 regulation of OIS. 
A. In normal BJ fibroblast cells, hyper-activation of RAS induces MAPK signaling cascade, including
AP-1 TFs. Activated AP-1 TFs control different cellular functions, including cell proliferation and
apoptosis. AP1 is recruited, among other enhancers, to EnhAP1-OIS1 and stimulates its activity.  This in
turn promotes the expression of the target gene FOXF1, diverting oncogenic signals into pre-senescent
pathway. B. Mutagenesis of the AP-1 binding site in EnhAP1-OIS1 abrogates its enhancer activity and thus
leading to decreased expression of FOXF1. This results in compromised induction of OIS and thus cells 
continue uncontrolled cell proliferation.
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Discussion
In this study, we first found that OIS-induced enhancers are enriched for the binding 
motif of AP1. Based on this finding, we perform a CRISPR screen focused on AP1 
motifs within enhancers that are activated upon oncogenic stress. We discovered a novel 
AP-1 bound enhancer, EnhAP1-OIS1, that is required for establishment of OIS and identified 
FOXF1 as the target that mediates this role. We propose a new role of AP1 in senescence 
via activation of FOXF1, providing an additional regulation of cell proliferation during 
senescence.
AP1 TFs are recruited to enhancer regions to drive oncogenic growth (24) and are broadly 
required for enhancer selection(25), suggesting a possible role of AP1 at enhancers. As 
a downstream target of RAS signalling pathway, AP1 is activated to target mitogen-
responsive genes (26,27). Earlier studies have shown that mRNA level and activity of AP1 
genes are attenuated upon entering replicative senescence (28,29). Altered AP1 activity 
is mainly due to loss of c-FOS expression and maintained JUN proteins, thus promoting 
JUN-JUN homodimers instead of FOS-JUN heterodimers (29,30). This suggests that 
loss of AP1 activity is possibly responsible for the irreversible growth arrest in senescent 
cells. Conversely, overexpression of c-FOS with increased AP1 activity is not sufficient 
to initiate DNA synthesis in senescent human fibroblasts (31). Therefore, AP1 is likely 
not the key factor that regulates senescence, but rather a downstream factor that fine-tune 
the senescence program under replicative stress (e.g. H-RAS activation). In addition, 
previous functional genetic screens did not indicate any of the AP1 family members as 
critical factors in OIS(20,32). Supporting this conclusion, CRISPR-mediated KOs of 
c-FOS and c-JUN did not result in any obvious bypass of OIS (Figure S8). However, it 
is possible that one or few targets of AP1 mediate OIS while others antagonize it, or are 
required for cell survival.
FOXF1 belongs to the Forkhead family of transcription factors. FOXA1 has been 
reported to promote senescence via activation of p16INK4a (33), and FOXO4 inhibition 
induces p53 nuclear exclusion, which results in apoptosis of senescent cells (34). The 
functions of FOXF1 remain to be determined, yet recent studies have implicated its role 
in lung regeneration by targeting genes of extracellular matrix and cell cycle progression 
(35), as well as promoting prostate cancer growth via MAPK pathway (36). To date, 
there has been no evidences of any connections between AP1, FOXF1 and OIS, possibly 
due to regulation via enhancers, rather than proximal promoters, as proposed in this 
study. It has been proposed that FOXF1 is a target gene of p53, which regulates cell 
migration and invasion (37); and that FOXF1 is a potential oncogene, which promotes 
rhabdomyosarcoma by repressing p21Cip1 (38). Here we provide the first evidence 
suggesting that FOXF1 is a potential tumour suppressor, regulating senescence in human 
cells. In addition, we generated double knockout cell lines (NT+p53 ko, sgRNA-AP169+ 
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p53 ko, sgRNA-AP171+ p53 ko, and FOXF1 ko + p53 ko), and we observed a strong 
senescence bypass phenotype (Figure S9A-B). Interestingly, we found an additive effect 
of proliferation in the EnhAP1-OIS1 ko and FOXF1 ko cell lines (sgRNA-AP169+ p53 
ko, sgRNA-AP171+ p53 ko, and FOXF1 ko + p53 ko) compared with NT + p53 ko cells 
(Figure S9B). This suggests that FOXF1 regulates OIS in a p53 independent manner. In 
parallel with the canonical p53 pathway, FOXF1 regulates the expression of a subset of 
cell cycle and ribosomal genes (Fig. 4). Further studies should explore the exact function 
of FOXF1 in regulating senescence.
We propose a model in which following oncogenic induction, AP1 TFs are activated to 
promote cellular proliferation in response to stimuli. However, under excessive exposure 
to RAS, AP1 is recruited to EnhAP1-OIS1 to promote the expression of FOXF1 to drive 
cells into senescence. Disruption of the AP1 binding site within EnhAP1-OIS1 results in 
attenuated activation of FOXF1, hampering full execution of the OIS program. We 
attempted to generate a FOXF1 overexpression cell line while targeting EnhAP1-OIS1, to 
rescue the senescence phenotype. However, this was not successful, possibly due to the 
intolerance of the cells under ectopic FOXF1 expression. This result show that although 
AP1 is activated by MAPK pathway, and stimulates the expression of many cell cycle 
genes, upon oncogenic stress it also mediates tumor suppressive effects.
Our current knowledge on cancer driver non-coding somatic mutations (SMs) is 
still very rudimentary, yet several studies suggested that the role of such SMs is 
underappreciated(39,40). Genome-wide analysis has revealed AP1 as a key factor at 
regulatory elements in cancers(41), and AP1 binding sites are frequently mutated in 
various cancer types (42). Analysing ICGC data, we found a somatic mutation within 
the AP1 motif of EnhAP1-OIS1 in a lung cancer patient, and validated its functional effect by 
using in vitro reporter assays (Fig. 2H). This suggests a possible cancer driver effect for 
somatic mutations in AP1 binding motifs. Our study further demonstrates the power of 
CRISPR-based screens in exploring the function of the noncoding genome.
Conclusions
Our study provides evidence that AP1 TFs are broadly stimulated during OIS and are 
localized to enhancer regions to activate specific gene programs. We show that AP1 
controls senescence program via EnhAP1-OIS1 and its target gene FOXF1. We propose that 
AP1 is a double-edged sword in regulating cell proliferation and senescence, providing 
a restrictive feedback on unlimited cell proliferation. 
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Figure S2. Mutation profiles of BJ-indRASG12V cells transduced with sgRNA-AP169 and -AP171. 
Genomic DNA of BJ-indRASG12V cells with the indicated sgRNAs was isolated, and EnhAP1-OIS1 region 
was PCR amplified, subjected to deep sequencing and analysed for mutations. Proportion of wild-type 
or mutated (by mismatch, deletion or insertion) base calls is indicated as a function of its distance 
from the Cas9 cleavage site. For sgRNA-AP169, the majority of the mutations are single nucleotide 
insertions, while for sgRNA-AP171 deletions around the cleavage site were more prevalent.
sgRNA-NT sgRNA-AP169 sgRNA-AP171 sgRNA-FoxF1
β-Gal staining
BrdU staining
Figure S3. Representative pictures of β-Gal assay and BrdU staining. 
A. Representative pictures of β-Gal assay and BrdU staining experiments used for the analysis of 
the results shown in Fig. 2-3. Each column represents the cells infected with the indicated sgRNA. 
The cells were treated with 4-OHT for 14 days prior analysis. Upper panel shows the β-Gal staining 
experiments with senescent cells stained as blue. Lower panel shows the BrdU staining experiments 
with cells incorporated with BrdU stained as green and nucleus stained as red.
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AP1 motif
Figure S4. Somatic mutation in the AP1 motif within EnhAP1-OIS1. 
Screenshots from ICGC portal show a single nucleotide substitution within the AP1 motif in EnhAP1-OIS1 
detected in a patient with lung cancer.
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FOXF1
Figure S5. RNA-seq analysis indicates FOXF1 as a target gene of EnhAP1-OIS1. 
Gene expression levels were measured in BJ cells targeted by either sgRNA-AP169, sgRNA-AP171 or 
sgRNA-NT negative control. Violin plots show the distribution of fold change of gene expression (in 
log2 base) calculated for the comparison between the sgRNA-AP169 and sgRNA-AP171 samples and the 
sgRNA-NT control. FOXF1 is marked by a rod dot. Its expression was markedly decreased by targeting 
EnhAP1-OIS1 by either sgRNA-AP169 or sgRNA-AP171.
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Figure S7. 3C experiment reveal direct interaction between EnhAP1-OIS1 and FOXF1. 
A. Genome browser presentation of the location of each primer used in 3C analysis. Constant primers
(C1, C2) used to amplify EnhAP1-OIS1 are indicated in black arrows. Negative control regions with no
interaction with EnhAP1-OIS1 are amplified with primers indicated in red arrows (N1-N4). FOXF1 regions
with potential interactions with EnhAP1-OIS1 are amplified with primers indicated in green arrows (P1-P8).
Agarose gel images from two independent biological replicates are shown with the expected sizes of the 
PCR products. The quantification of the gels was performed by normalizing to the primer efficiencies.
Values shown are further normalized to the quantification value of P1.  B.  Sanger sequencing results
from the indicated PCR products. Csp6I restriction sites are highlighted in yellow. The PCR were
performed using the indicated primer pairs.
sgRNA-Fos sgRNA-Jun
Figure S8. Disruption of Fos and Jun could not bypass senescence. 
Representative pictures of BrdU staining experiments with sgRNAs against c-Fos and c-Jun genes. BJ 
cells were treated with 4-OHT for 14 days. Each column shows two pictures from the same experiment.
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Figure S9. FOXF1 function is independent of p53 during OIS. 
A. Representative images of the SA-β-gal staining of cells under the indicated conditions and after 14 
days 4-OHT treatment. B. The proliferation levels of the various sgRNA-transduced BJ-indRASG12V cells 
(indicated in the figures) was quantified using BrdU assay, (* p <0.05, two-tailed Student’s t-test). For 
every condition, the percentage of BrdU-positive cells was normaliz`ed to control cells (NT+p53 ko). 
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Cancer is a common disease worldwide, but unfortunately its treatment is limited and 
inefficient. Understanding the tumorigenesis and cancer development can provide 
additional fundamental knowledge to help develop novel cancer diagnosis and treatment 
tools. Cellular senescence is a mechanism that suppresses tumorigenesis following the 
emergence of genetic alterations. Investigation and identification of regulators in cellular 
senescence will help us to better understand tumorigenesis, allowing the identification of 
new biomarkers or therapeutic targets for cancer treatment.
Over the past few decades, many lncRNAs have been characterised as important players 
in a myriad of biological processes, such as differentiation, proliferation, development, 
as well as in a variety of human diseases including cancer (1–5). However, the roles and 
functions of lncRNAs in OIS have not been fully elucidated. OIS is a major cellular 
senescence type which poses a critical barrier to cancer, but so far, few studies have 
described lncRNAs in OIS. It has been shown that lncRNA-MIR31HG is a senescence 
modulator in BRAFV600 induced senescence in TIG3 cells (6). Loss of MIR31HG 
reduced cell growth and promoted a strong senescence phenotype by regulating the 
tumour suppressor p16INK4a. In the first study described in this thesis (chapter 2), we 
contributed to the understanding of the function of lncRNAs by presenting the lncRNA-
OIS1 as a new regulator of cellular senescence (OIS). LncRNA-OIS1 is a long non-
coding RNA whose expression is upregulated during OIS and knockdown of lncRNA-
OIS1 bypassed the OIS. The shRNAs were validated from the screen, confirming that 
knockdown of the corresponding lncRNAs by shRNAs induced this senescence bypass 
phenotype. However, the off-target effect existed when more shRNAs were included 
for validation. Recent studies have shown that the CRISPR-Cas13 system can be used 
to edit the RNA. Remarkably, Cas13 has less off-target effect and was more effective 
than siRNA (7, 8). It is, therefore, possible that the use of CRISPR-Cas13 to manipulate 
lncRNA expression may identify in the future additional key lncRNAs that regulate OIS.
Furthermore, the knockdown of lncRNA-OIS1 affects the activation of the nearby gene 
DPP4 upon oncogene induction. Further investigation indicated that DPP4 is the target 
gene of lncRNA-OIS1 in the context of senescence. We demonstrated that loss of DPP4, 
similar to lncRNA-OIS1 knockdown, resulted in bypass of senescence. We reverted 
the bypass of senescence induced by the lncRNA-OIS1 knockdown through ectopic 
expression of DPP4. However, exactly how lncRNA-OIS1 controls DPP4 expression 
and how DPP4 modulates senescence remain to be investigated. Nevertheless, it is 
hypothesised that lncRNA-OIS1 expression is required for either the recruitment of 
essential transcription factors to activate DPP4 or alternatively by inhibiting the binding 
of a transcriptional repressor protein. The results presented in chapter 2 were partly 
confirmed by Kyoung Mi Kim et al. (9), who described the identification of DPP4 as 
a regulator and marker for senescence, a promising target of therapeutic intervention to 
eliminate senescent cells. 
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As mentioned in the introduction, the bi-directional transcription of eRNAs is the 
hallmark for active enhancers. Global Run-On sequencing (GRO-seq) was used to 
detect eRNAs, identifying 1821 regulatory elements activated upon RAS induction in 
BJ cells. In chapter 3, it was established that those OIS-induced regions (enhancers) 
are significantly enriched for the AP1 binding motif. Genome-wide functional screen 
focusing on the AP1 motif within these enhancers uncovered the role of a novel AP1 
associated enhancer, EnhAP1-OIS1, in regulating OIS through its target gene FOXF1. AP1 
is an important transcription factor consisting of FOS-JUN (heterodimer) or JUN-JUN 
(homodimers). The FOS-JUN heterodimer is relatively more stable and has higher 
DNA-binding affinity than JUN-JUN homodimers. It has been reported that AP1 binds 
with enhancers to drive oncogenic growth and is required for enhancer selection (10, 11), 
indicating a critical role in regulating enhancers. AP1 is a well-known downstream target 
of the RAS signalling pathway, which is responsible for mitogen-related genes (12, 13). 
Previous studies have shown that AP1 mRNA level and activity are attenuated when 
cells enter replicative senescence (14, 15). It has been demonstrated that AP1 activity is 
required for initiation of DNA synthesis. Interestingly, AP1 activity is lost during cellular 
ageing (16), suggesting the loss of AP1 activity is responsible for the irreversible cell 
cycle arrest in senescent cells. However, c-FOS overexpression with rescued AP1 activity 
is not sufficient for DNA synthesis in the senescent human fibroblasts (17). Therefore, 
AP1 is more likely a downstream factor regulating senescence under replicative stress 
(e.g. H-RAS activation). It is worth noting that none of the AP1 family members were 
demonstrated as critical players in OIS based on previous functional genetic screens (18, 
19). Also, the OIS bypass phenotype was not observed on c-FOS knockout and c-JUN 
knockout, strongly supporting the previous conclusion. Why AP1 regulates OIS, but 
the knockout of AP1 did not show OIS bypass still requires further investigation. One 
possibility is that some AP1 target genes mediate OIS, however, others antagonise it or 
are required for cell survival.
This thesis contributed to the understanding of AP1 associated enhancer modulating 
OIS through FOXF1, providing evidence indicating that FOXF1 is a potential tumour 
suppressor that regulates senescence. Other studies have already shown the role of FOXF1 
in lung regeneration by targeting ECM genes and cell cycle progression (20). FOXF1 
also promotes prostate cancer growth through the MAPK pathway (21). Moreover, 
FOXF1 has been proposed to be a target of p53 to regulate cell migration, invasion (22) 
and promote rhabdomyosarcoma by repressing p21Cip1 as a potential oncogene (23). How 
exactly FOXF1 modulates OIS is not clear. Our results indicate that FOXF1 regulates 
OIS in a p53 independent manner, but more studies are required to explore the function 
of FOXF1 in OIS.
YAP is another crucial transcription factor of the Hippo pathway regulating organ growth 
and tumorigenesis. When Hippo signalling is inactive, YAP and its paralogue TAZ 
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translocate to the nucleus and bind DNA indirectly through interaction with the TEAD 
family of transcription factors to regulate target genes (24, 25). Hippo signalling ablation 
or expression of constitutively active YAP leads to increased organ size, oncogenic 
growth or even occurrence of cancers (10, 26–29). The Hippo pathway is extremely 
important in cancer, which makes this pathway a potential target for cancer therapeutics. 
Over the past decades, numerous YAP-mediated genes have been discovered and 
characterised as critical players in YAP-mediated proliferation and oncogenesis. 
However, the transcriptional function of YAP remains largely unknown, especially 
the role of YAP-mediated enhancers. In chapter 4, a stable cell line was generated 
by overexpressing the constitutively active YAP(5SA) and AP1. As expected, the same 
oncogenic growth phenotype was observed as previously reported (10). It is known that 
YAP/TAZ/TEAD together with AP1 can bind with enhancers to drive oncogenic growth 
(10). However, how many enhancers are functionally important for the oncogenic growth 
and epithelial-mesenchymal transition phenotypes that are induced by deregulated YAP 
and AP1 remain unknown. We successfully performed a functional screen and identified 
seven enhancer targets of YAP. Some well-known genes, such as Myc and CCND1, 
were predicted as targets of two identified enhancers based on our RNA-seq. Notably, 
we found one novel enhancer whose target gene is supposed to be Tram2. All target 
enhancers are required for YAP-oncogenic function, but more detailed investigations 
and analyses of the function of the identified enhancers and target genes are required. 
Taken together, chapter 4 described an important function of YAP-mediated enhancers 
with potentially influential implications in cancer biology.  
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Summary
The genetic information of a cell is held within genes in its DNA. Transcription of DNA 
into RNA is the first step, followed by translation of mRNA into proteins. Although, the 
vast majority of functions of the cells are carried out by proteins, DNA and mRNA control 
the “fate” of corresponding proteins. Interestingly, the genetic information required for 
protein (coding DNA sequence) production comprises an extremely small portion (around 
2%) of the whole human genome sequence. It was thought that the remaining 98% of the 
human genome sequence was “junk DNA” without any biological function for a very 
long time. Discovery and characterisation of “junk DNA” that regulates the expression 
of genes challenged this “idea”. Until now, more and more studies have revealed that 
the so-called “junk DNA” has biological functions beyond protein-coding DNA. There 
are numerous functional “junk DNAs”, referred to as regulatory elements, in the human 
genome. The regulatory elements can be generally classified into two different groups, 
DNA elements (promoters, enhancers, and insulators) and RNA elements (lncRNAs, 
MicroRNA). Among them, enhancers and lncRNAs have been reported to play a critical 
role in the regulation of gene expression. 
Cancer is a complicated “DNA disease” originating from “changes” in the DNA 
sequence, especially within the genes that control cell proliferation and survival. It is of 
note that the vast number of genetic variants associated with human diseases, especially 
cancer, reside in non-coding regions. Clarifying how the non-coding regions affect gene 
expression and contribute to the development of disease might have future implications 
in the diagnoses and treatment of those diseases, especially cancer. In this thesis, we 
described the functional identification of novel regulatory elements for OIS and YAP-
mediated oncogenic growth.
Chapter 2 explored the understanding of lncRNAs function in RAS-induced senescence 
and addressed lncRNA-OIS1 as a new regulator in cellular senescence (OIS). We 
performed a functional enrichment screen using the shRNAs library to target the changed 
lncRNAs during OIS, showing that knockdown of lncRNA-OIS1 affects the activation 
of the nearby gene DPP4 on RAS induction. In addition, we identified that DPP4 is the 
target gene of lncRNA-OIS1 to regulate senescence, demonstrating that loss of DPP4 
resulted in bypass of senescence. We reverted the bypass of senescence induced by the 
lncRNA-OIS1 knockdown through ectopic expression of DPP4. Thus, our findings 
suggest that DPP4 itself can be used as an additional senescence marker in the future.
In chapter 3, we identified that some OIS-induced regions (enhancers) are significantly 
enriched for the AP1 binding motif. A genome-wide functional screen focusing on 
the AP1 motif within these enhancers revealed that a novel AP1 associated enhancer, 
EnhAP1-OIS1, regulated OIS through the target gene FOXF1. We provided the first evidence 
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indicating that FOXF1 is a potential tumour suppressor to regulate senescence, showing 
that FOXF1 regulates OIS in a p53 independent manner. 
Chapter 4 focused on transcription factor-YAP-related enhancers, generating a new 
cell line by overexpressing the constitutively active YAP(5SA) and AP1. We observed 
the oncogenic growth phenotype with accelerated cell proliferation and cellular 
morphological changes in this cell line. We successfully evaluated the efficiency of 
the CRISPR approach and performed the functional screen, identifying several novel 
enhancers required for YAP-mediated proliferation, providing evidence that YAP 
controls proliferation through different targets. We first predicted the target gene of one 
novel enhancer (enhancerTram2) is Tram2 (translocation associated membrane protein 2). 
More investigations need to be done to uncover the function of Tram2 in cancer.
Cellular senescence is a state of irreversible growth arrest which can be induced by 
different stimuli, including telomere shortening, DNA damage, oxidative stress or 
oncogenic activation. Chapter 2 and 3 focused on oncogene-induced senescence, 
presenting several novel regulators of OIS and discussed how their identification enables 
a better understanding of how tumour cells bypass intrinsic safety mechanisms. YAP 
is frequently activated in many tumours and it is the main factor in the Hippo pathway 
controlling cell proliferation, organ growth, cell death, and differentiation. Chapter 
4 presented several potential targets that can be used for diagnoses and treatment for 
cancers.
In summary, this thesis investigated and characterised how the non-coding regions 
regulate gene expression based on different cellular systems, thereby contributing to the 
understanding of the “dark matters” in the human genome.
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Samenvatting
De genetische informatie van een cel wordt in de genen in zijn DNA gehouden. 
Transcriptie van DNA naar RNA is de eerste stap, die gevolgd wordt door translatie 
van boodschapper-RNA (mRNA) in eiwitten. Hoewel de meeste functies van de cellen 
worden uitgevoerd door eiwitten, regelen het DNA en mRN het “lot” van overeenkomstige 
eiwitten. Interessant is dat de genetische informatie vereist voor eiwit productie ( de 
coderende DNA-sequentie) een extreem klein deel (ongeveer 2%) van de gehele humane 
genoomsequentie omvat. Er werd gedurende een zeer lange tijd aangenomen dat de rest 
98% van de sequentie van het menselijk genoom “rommel-DNA” was zonder enige 
biologische functie. Ontdekking en karakterisering van ‘rommel-DNA’ dat de expressie 
van genen reguleert, daagde dit ‘idee’ uit. Tot nu toe lieten meer en meer onderzoeken 
zien dat het zogenaamde “rommel-DNA” een biologische functie heeft die verder 
gaat dan eiwit-coderend DNA. Er zijn talloze functionele stukken “rommel-DNA”, de 
regulerende elementen, in het menselijk genoom. De regulerende elementen kunnen in 
het algemeen worden geclassificeerd in twee verschillende groepen: DNA-elementen 
(promotors, enhancers en isolatoren) en RNA-elementen (lncRNA’s, MicroRNA). Onder 
hen werden enhancers en lncRNA’s veelvuldig beschreven in de literatuur vanwege de 
cruciale rol die ze spelen in de regulatie van genexpressie.
Kanker is een gecompliceerde “DNA-ziekte” die voortkomt uit “veranderingen” in de 
DNA-sequentie, vooral binnen de genen die de cel proliferatie en overleving regeluren. 
Het is belangrijk om op te merken dat het grote aantal genetische varianten geassocieerd 
met menselijke ziekten, met name kanker, voorkomt in niet-coderende regio’s. 
Verduidelijken hoe de niet-coderende regio’s de genexpressie beïnvloeden en bijdragen 
aan de ontwikkeling van ziekten zoals kanker, kan toekomstige implicaties hebben 
voor de diagnose en behandeling van die ziekte. In dit proefschrift beschrijven we de 
functionele identificatie van nieuwe regulatoire elementen voor oncogen geïnduceerde 
senescence en YAP-gemedieerde oncogene groei.
In hoofdstuk 2 hebben we de functie van lncRNA in RAS-geïnduceerde senescence 
onderzocht en het lncRNA-OIS1 geïdentificeerd als een nieuwe regulator in cellulaire 
senescence (OIS). We voerden een functionele verrijkings screen uit door gebruik te 
maken van shRNA’s om de lncRNA’s die in het proces van OIS een rol spelen, te targeten. 
We toonden aan dat knock-down van lncRNA-OIS1 invloed heeft op de activatie van het 
nabijgelegen gen DPP4 na RAS-inductie. En we hebben ook vastgesteld dat DPP4 het 
doelwit gen is van lncRNA-OIS1 om senescence te reguleren. We hebben aangetoond 
dat verlies van DPP4 resulteerde in bypass van senescence. We hebben de bypass van 
senescence, veroorzaakt door de knock-out van lncRNA-OIS1 teruggedraaid door 
ectopische expressie van DPP4. DPP4 zelf kan in de toekomst worden gebruikt als een 
extra marker voor senescence.
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In hoofdstuk 3 hebben we enkele OIS-geïnduceerde regio’s (enhancers) geïdentificeerd 
die significant verrijkt zijn voor het AP1-bindingsmotief. Daarom hebben we een genoom-
brede functionele screen uitgevoerd die gefocust is op het AP1-motief in deze enhancers. 
Hiermee hebben we een nieuwe AP1-geassocieerde enhancer, EnhAP1-OIS1, ontdekt 
die OIS reguleert via het doelwit gen FOXF1. We hebben het eerste bewijs geleverd dat 
aangeeft dat FOXF1 een potentiële tumorsuppressor is om senescence te reguleren. We 
hebben ook aangetoond dat FOXF1 OIS op een p53 onafhankelijke manier reguleert.
In hoofdstuk 4 hebben we ons gericht op enhancers die gereguleerd worde door een andere 
transcriptiefactor -YAP. We hebben een nieuwe cellijn gegenereerd door het constitutief 
actieve YAP (5SA) en AP1 tot overexpressie te brengen. We observeerden het oncogene 
groeifenotype met versnelde celproliferatie en cellulaire morfologische veranderingen in 
deze cellijn. We hebben met succes de efficiëntie van CRISPR-benadering geëvalueerd 
en een functionele enhancer screen uitgevoerd. We identificeerden verschillende nieuwe 
enhancers die allemaal nodig zijn voor YAP-gemedieerde proliferatie en het bewijs 
leveren dat YAP door verschillende doelen de proliferatie regelt. We voorspelden eerst 
dat het doelwit gen van een nieuwe enhancer (enhancerTram2) Tram2 is (translocatie-
geassocieerd membraaneiwit 2). Meer onderzoek moet worden gedaan om de functie 
van Tram2 in kanker bloot te leggen.
Cellulaire senescence is een toestand van onomkeerbare groeistop die kan worden 
geïnduceerd door verschillende stimuli, waaronder telomeer verkorting, DNA-schade, 
oxidatieve stress of oncogene activering. Hoofdstuk 2 en 3 concentreerden zich op de door 
oncogen geïnduceerde senescence en presenteren verschillende nieuwe regulatoren van 
OIS en bespraken hoe hun identificatie ons in staat stelt beter te begrijpen hoe tumorcellen 
de intrinsieke veiligheidsmechanismen omzeilen. YAP wordt vaak geactiveerd in een 
groot aantal tumoren en het is de belangrijkste factor in Hippo pathway die celproliferatie, 
orgaangroei reguleert, en invloed uitoefent op celdood en differentiatie. Hoofdstuk 4 
presenteert verschillende potentiële doelen die kunnen worden gebruikt voor diagnoses 
en behandeling van kankers.
Samenvattend, in dit proefschrift hebben we onderzocht en gekarakteriseerd hoe de 
niet-coderende regio’s de genexpressie reguleren op basis van verschillende cellulaire 
systemen, wat heeft bijgedragen aan het begrip van de “dark matter” in ons genoom.
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